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Abstract

Current Good Manufacturing Practices (cGMP ' s) were developed to keep the
public safe and ensure quality products. Technological evolution of the industry
resulted in cGMP requirements which could not keep pace, and ultimately had a
restrictive effect on daily operations and process improvements for pharmaceutical
manufacturers. In response, the FDA has recently released new Guidances for
Industry, PAT-A Framework for Innovative Pharmaceutical Development,
Manufacturing, and Quality Assurance and Pharmaceutical cGMP ' s for the 21st
Century-A Risk-Based Approach, to encourage innovation in the pharmaceutical
industry. The current focus is to understand the product, the manufacturing process
and operations rather than the previous focus on product testing and release. Other
industries have developed innovative approaches to competitive improvement and it
is important to learn from their successes and failures .
The aim of this study is to identify critical areas for improvement in current
pharmaceutical manufacturing practices and to explore solutions to these problems
using principles found outside of the pharmaceutical industry. A facility producing
pharmaceutical products under cGMP' s will be evaluated to gain a "baseline"
understanding of current manufacturing practices. Critical and problematic areas
will be identified as well as potential opportunities to incorporate external industry
practices, with a focus on the Toyota Production System®, to improve the
manufacturing process.
A ProModel® simulation was developed in as a proof of concept to evaluate
proposed improvements to the system. This simulation was run with a number of

theoretical changes to the scenario to evaluate the effects and interactions of the
proposed improvements. These areas of improvements include: Shrinking traditional
batching rules to create a more semi continuous production system, cross training
personnel on equipment and responsibilities, and the addition of parallel machines at
the equipment bottleneck.
Results from the simulation experimentations indicated that significant
improvements to product throughput time can be achieved.

While all three

individual factors studied were found to be significant, the greatest gains were
achieved using a combination of batch rule changes and cross training of personnel.
Changing the batching rules was found to have the greatest effect on reducing
throughput times, due to the drastic reduction of time spent waiting to batch in the
system. Cross training resulted in increased capacity in the bottleneck machine with
availability during all hours of operation.

While parallel machining did achieve

improved throughput times when compared to the current state of the system, the
additional machine was not justified when compared with the scenario yielding
superior results.
Lean manufacturing and other alternative techniques should be explored in
the pharmaceutical industry to improve current systems and utilized early in the
development of new systems.

This case study represents a number of possible

opportunities for specific areas of improvement as well as suggesting an overall
change in manufacturing mindset. The pharmaceutical industry can learn a great
deal from outside industries where competitiveness is required to ensure solvency.
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Chapter 1

1.0 Introduction

Chapter one aims to orient the reader with a brief history of both general
manufacturing and pharmaceutical manufacturing. The history discussed is not
intended as a comprehensive review of manufacturing, rather it will give the reader
perspective with regard to the origins and ongoing evolution of the state of
manufacturing. This chapter will also describe the general study objectives of this
thesis.
1.1 Brief History of Manufacturing

In 1776 Adam Smith published "An Inquiry into the Nature and Causes of
the Wealth of Nations" and introduced the concept of the division of labor. Smith
felt that by dividing complex jobs which were previously performed by skilled
artisans (carpenters, smiths, etc .. .) into simplified tasks, greater levels of efficiency
could be achieved. His experiments first assessed the production of metal pins by
unskilled laborers using traditional craft methods, which required all aspects of
manufacturing.

He then compared these laborers to a group which had the

manufacturing process divided into one or a few simple tasks. Each laborer was
responsible for their individual area of pin manufacturing and he found a large
increase in productivity. He attributed the increased output to three reasons: 1. An
increase in the operator's dexterity due to simple and repetitive tasks.

2.

Minimization of travel time because the product moved and the people did not and 3.
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Tools used in the manufacturing can be optimized based on the operator's superior
knowledge of the process (Smith, 1776).
The introduction of interchangeable parts for the manufacturing of muskets
by Honore Blanc in the late 1700's also signaled an important milestone in the
evolution of manufacturing.

By creating interchangeable parts through the

standardization of templates and equipment, he replaced artisan craftsman and
enabled unskilled laborers to be trained with manufacturing tools to generate greater
production numbers at lower costs. This new method was adopted in many other
industries throughout the world and facilitated the rapid growth of mass production
(Gillespie, 1998; Hopp, 2001).
In 1913, Henry Ford introduced a continuously moving assembly line which
allowed workers to remain in their workstations to add parts to cars as they passed
by. Parts were supplied to workers through conveyors and timed to keep workers
well stocked with necessary components.

This new method drastically reduced

automobile assembly times, lowered vehicle costs, and propelled the Model T to a
dominant share of the market at the time (The Henry Ford Museum, 2003). The
expensive, single function machinery limited flexibility and required many buffers of
supplies, workers and storage space in order to maintain a smooth operation.
Additionally, changing between products was an expensive and time consuming
process due to system rigidity, and resulted in fewer options for consumers
(Womack, 1990).
Ford's breakthrough changed the face of the automobile industry, and
Toyoda Kiichiro of Toyota Motors, was eager to learn from the automotive giant. In
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1933 Kiichiro stated, "We shall learn production techniques from the American
method of mass production. But we will not copy it as is. We shall use our own
research and creativity to develop a production method that suits our own country's
situation" (Ohno, 1988).

The Toyota Production System was founded on the

principle of waste elimination, utilizing autonomation and just-in-time principles.
Under the guidance of Taiichi Ohno, this system evolved greatly from its inception
to the present day concept of "World Class Manufacturing," with an overriding goal
of continual and rapid improvement while maintaining flexibility (Schonberger,
1986). These concepts have been termed "lean production" (Womack, 1990) and
have resulted in the commitment to improve industry flexibility and competitiveness.

1.2 Brief History of Pharmaceutical Manufacturing
In 1938, The Food and Drug Administration (FDA) enacted the Federal
Food, Drug, and Cosmetic Act and subsequently developed the Code of Federal
Regulations (CFR), which contained current Good Manufacturing Practices
(cGMP's). These practices were intended to keep the public safe and ensure quality
products (FDA, 2006a). The pharmaceutical industry developed rapidly in response
to the great need for penicillin and medical supplies during World War II. Following
the war, manufacturers began researching and developing new drugs to expand the
industry. Drug discovery evolved over the next 50 years from traditionally random
occurrences to a highly focused methodology. Screening of target receptors and
functional chemical structures makes it possible to identify potential successful
therapeutic opportunities from a large pool of candidates (Ratti, 2001 ). While drug
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discovery experienced rapid growth with relatively little regulatory oversight, the
manufacturing areas of the industry were under the strict guidance of the FDA's
cGMP's. These regulations resulted in a strong commitment to quality and industry
adoption of Total Quality Management (TQM) (Ghobadian, 1995), Statistical
Process Control (SPC), Six Sigma (Swarbick, 2006), and other quality programs.
Rapid technological evolution of the industry resulted in cGMP's which could not
keep pace, and ultimately had a restrictive effect on daily operations and process
improvements for pharmaceutical manufacturers. The industry fell behind other less
regulated manufacturing industries, where innovative practices and procedures were
critical for global competition.
1.3 Study Objectives

The aim of this study is to identify critical areas for improvement in current
pharmaceutical manufacturing practices and to explore solutions to these problems
using principles found outside of the pharmaceutical industry. The study will be
divided into two phases:
Current State:
1. The

evaluation

of

a

manufacturing

facility

currently

producing

pharmaceutical products under current Good Manufacturing Practices is to
gain a "baseline" understanding of the state of the art of manufacturing.
Using this knowledge to develop an accurate model of the system will
identify critical and problematic areas.
Future State:

4

2. The utilization of external industry practices, such as the Toyota Production

System®, system designs to evaluate the introduction of continuous or semi
continuous manufacturing. Other lean ideals and outside industry approaches
will be used to improve the current manufacturing process and develop a new
model. Quantitatively assess current processing standards and metrics with
the newly designed model for pharmaceutical manufacturing based on
manipulation of critical parameters.

The theoretical improvements will

follow the new FDA guidance documentation, as well as explore new
boundaries.

1.4 Study Significance

Currently, there is little publicly available information about improving
processes through innovational approaches. The National Institute for
Pharmaceutical Technology and Education (NIPTE) has identified that while
manufacturing is a significant expense to industry, there is very little industry and
federal research funding in this area as compared to drug discovery. The lack of
interest in funding manufacturing and processing research can be attributed to both
the pharmaceutical industry and the FDA. The pharmaceutical industry is focused on
bringing their product to the market place as rapidly as possible prior to the
expiration of the patent in order to recoup the large investment made during the
development process. The FDA is a regulatory agency concerned with product
safety and has fostered a long tradition of discouraging risk taking involved in
technological changes. As a result, industry has little incentive to invest dollars

5

geared at the advancement of product/process development and manufacturing
technologies/practices. Additionally, the National Institute of Health (NIH) is
focused on funding predominately discovery related basic research, while the
National Science Foundation has focused on manufacturing industries that are
critical to the economy but struggling or threatened (Couts, 2006).
This research will serve as a model for pharmaceutical processing in order to
encourage novel approaches to manufacturing, through specific and system wide
solutions. Ideally this research will serve small to medium sized pharmaceutical
manufacturers who are considering or implementing changes in their processes,
where simply improving their current system will be inadequate to meet the future
needs of manufacturing. Through experimental and statistical modeling, conclusions
can be drawn about altering the traditional mentality of manufacturers to improve
production. Additionally, because the pharmaceutical industry is so diverse, research
must be conducted in all aspects of the field.

While powder based processing

(tablets, capsules, etc ... ) and biotechnology has received wide attention, smaller
sectors have not been explored in depth. Contract manufacturing can be considered
a specialty area of the pharmaceutical industry requiring flexible personnel,
equipment and production capabilities. This research should also be considered by
other regulated industries such as food, cosmetics, nutraceutical, etc. for viable
methods for improvement.

6

t.5 Chapter Review

Manufacturing has evolved over the past two hundred years and has created
different levels for operational standards throughout industries. It is important to
understand how the pharmaceutical industry was born and its evolution, to better
grasp the current state of pharmaceutical manufacturers. Identifying developmental
differences in outside industries will encourage greater fundamental understanding of
why pharmaceutical manufacturing is unique.

7

Cbapter2
2.0 Tools Utilized by Other Industries

Chapter two will give the reader an overview of the current state of lean
manufacturing and commonly used lean tools in order to familiarize the reader with
methods used in outside industries. Value Stream Mapping®(VSM) is discussed as
an important method to identify problematic areas.

System configuration is

addressed with regard to flexibility and responsiveness through parallel machining.
2.1 Current State of Lean Manufacturing

Toyota is the developer and leader in the use of lean manufacturing, which
has been widely adopted with applicability to any industry. Prior to beginning
improvement, there must be an understanding of the current system. In order to gain
a baseline understanding of the current system, VSM has been used as a critical first
step in the process. The process involves the investigation and recording of all
activities involved with manufacturing of a product from raw materials to finished
goods. By mapping the overall process, a systemic view can be created to evaluate
total efficiency instead of individual efficiencies or areas. The map includes two
classes of work: 1. Work that adds value to the product as defined by the customer
(value added) and 2. Non-value added work. By addressing both types of work, a
strategy can be devised to implement lean tools to decrease non-value added work
and create a long term vision. The long term vision can be shown through a future
state map which would employ the improvements and their estimated effects on the
system (Hall, 2001).
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Figure 1.

Example of a Current State Map with additional environmental data (US

EPA, 2006a)

Figure 1 is an example of a current state map used by the Environmental
Protection Agency (EPA). Definitions of the icons used in this value stream map can
be found in appendix I. The current state map is comprised of three basic elements:
"l. Product flow is the path(s) the product take through production, before being
shipped to the customer. 2. Information flow is how information is shared and
communicated during the production process. 3. Material flow deals with how
incoming material is moved and replenished and in what quantities during
production" (Hall, 2001 ).
To create an accurate depiction of the three flows in the map, there must be
accurate data from the production floor. "Gemba" is defined by Liker (2004) as the
"actual place" and is the first step used by Toyota® when solving a problem. The
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concept reinforces the need for first hand knowledge and challenges conventional
management methods of system reports and computer analysis. While many tools
can be utilized by personnel, it is important to have a firm grasp on the actual
situation. In order to illustrate the benefits of a VSM, an example is given. The EPA
collected the following pieces of data to create their current state map:
•

Cycle time: The average time a specific routing spends from the point of
release at the beginning of the routing until it reaches an inventory point at
the end of the routing (Hopp, 2001).

•

Change Over Times: The total amount of time it takes to change machinery,
tools, personnel, etc ... from the last unit of good production at normal line
efficiencies to the first good production unit of another product at normal line
efficiency (Henry, 2001).

•

Total Lead Time: The EPA used throughput time, (composed of processing
time, setup time, move time, plus waiting time) (Askin, 1993) plus delivery
time to calculate the total time from the release of the product to the shop
floor to the time of delivery.

•

Number of operators at each station: Additional information about manpower
requirements versus actual staffing.

•

Inventory levels: The amount and locations of the three inventory types is
considered. Raw materials are used to make components and sub assemblies,
work-in-process are materials and components waiting to be completed, and
finished goods are completed products.
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•

Uptime (Utilization): The fraction of time the system or machine is not idle
for lack of parts, calculated by dividing the arrival rate of parts by the
effective production rate of the machine. The effective production rate is the
maximum average rate at which the workstation can process parts, while
accounting for failures, setups and other pertinent factors over the planning
period of interest (Hopp, 2001 ).
Additionally, value stream maps can contain many more pieces of data

dependent on the scope and depth of the project. Work schedules and time available
to manufacture is important when calculating run ratios, which divides total available
time to manufacture by number of good parts. Scrap rates, batch sizes, and other
production information are useful in gaining an accurate portrait of the system.
While much of the focus of Value Stream Mapping® is based on
understanding the value added time and reducing the percentage of non-value added
time, the EPA measured the baseline usage of raw materials in an effort to calculate
the value added materials. The materials line drawn below the operational time line
differentiates between the two classes of materials.

The total amount of raw

materials used in each process and the amount of materials that are actually
incorporated into the product add value to the consumer. Operations chosen for
assessment of material usage are indicated by the EHS (Environmental Health &
Safety) oval icon based on data collection and expertise in the field.
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Lean techniques, which will be discussed in detail later, such as
Kaizen events, Kanban systems, Just-In-Time production and other strategies to
eliminate waste and improve production flow, were evaluated to determine where
decreases in the quantity of raw material usage could be achieved. The EPA then
created an action plan for these areas of opportunity in order to decrease wasted
materials in each operation. New values were then calculated and changes in flow
patterns (material, informational, production) are expressed in the future state map,
found in figure 2.
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Figure 2. EPA Future State Value Stream Map (EPA, 2006a)
2.2 Tools for Leaner Manufacturing

Lean manufacturing has been considered to capitalize on the advantages of
both mass production and artisan crafting. Cross trained workers are defined as
"workers trained over time to perform a variety of tasks within their work area"
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(Askin, 2002) and then often rotated throughout the positions. Utilizing cross trained
employees with flexible autonomated processing equipment enables the production
of a wide variety of products in high volumes. "Production is lean if it is
accomplished with minimal waste due to unneeded operations, inefficient operations,
or excessive buffering in operations" (Narasimhan, 2006). It is considered "lean"
because it utilizes far fewer resources, such as worker effort, production/storage
space, on site inventory, less equipment investments while striving to achieve defect
free processing (Womack, 1990).

2.2.1 Waste
In order to improve any company's leanness, it is important to identify and
address the seven forms of waste which were identified by Taiichi Ohno of Toyota®
(Ohno, 1988):
1) Defects: Parts that are manufactured but do not meet specifications
2) Waiting: Operators/equipment that is starved for work due to a lack of
materials, equipment, or pertinent information.
3)

Motion: Non value added movement of personnel, inventory, and/or
equipment.

4) Over-Processing: Any extra operations that are not required to
manufacture a product.
5) Over-Production: Making more product than the customer has ordered.
6) Inventory: Having excess raw materials, work-in-process, and finished
goods.
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7) Inefficiency:

Using excess material to process; people wasting time,

ideas, effort, and time, and under usage of capacity (Allen & Robinson,
2001).
The following lean techniques were developed in the pursuit of achieving
zero wastes.

2.2.2 Autonomation

Autonomation (Jidoka) in Japanese has two distinct meanings: I) A change
from a manual process to a machine process. 2) Automatic control of defects or
automation with a human mind (Monden, 1998). Machines normally operate at very
high rates in manufacturing organizations; when dies or tools break there is a rapid
proliferation of defective products if the machine is incapable of differentiating
between acceptable and defective products.

The founder of Toyota Motor

Company®, Toyoda Sakichi, invented an auto-activated weaving machine capable of
instantly stopping if any of the necessary threads broke.

This was a significant

finding which manifested into machinery in Toyota® plants that are equipped with
detection sensors linked to automatic stopping devices. Additionally, workers are
empowered and encouraged to stop production if they feel an error is occurring.
Machinery stoppage requires immediate attention to repair and improve the system.

If the machine can not be fixed in a set period of time, five minutes for example, then
all members of the production team become involved with a repair solution because
the entire production line is stopped. The cartoon below, figure 3, is a simple
example but shows two scenarios, the top portion represents a traditional automated
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machine which will produce whether the products are good or defective. In the
lower portion, there is the addition of a stop button which the machine can activate
itself in addition to a siren on top of the machine alerting the operator that there is a
problem. Ohno said, "A problem early in the process always results in a defective
product later in the process. This will stop the production line or change a plan
whether you like it or not" (Ohno, 1988).

Figure 3. Automation versus Autonomation (Hirano, 1987)
2.2.3 Error-Proofing

The term "Baka-Yoka" (idiot proofing) was first used by Shigeo Shingo, and
evolved into, "Poka-Yoka" (fool-proofing) (Shingo, 1985) and is now widely
recognized as error-proofing. This technique places various checking devices on
equipment and tools to remove the potential for error and ultimately the creation of
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defects. A simple example can be seen in figure 4a, where an electrical socket could
potentially be plugged into the incorrect charge.

Figure 4a. Electrical connection before error-proofing (QS Consult, 2006)

This error could cause an electrical short and would result in a defective
connection and an unusable product. When error-proofing is implemented, the part
is redesigned to prevent the erroneous connection from being made.

Figure 4b

below depicts how a simple modification can achieve this result and remove the
potential for error from the operator or manufacturing equipment.

Figure 4b. Electrical connection after error-proofing (QS Consult, 2006)

Error-proofing is used extensively throughout the Toyota Production System
m conjunction with autonomation to minimize the production and passage of
defective parts to the next process and to the ultimate consumer (Ohno, 1988).
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2.2.4 Just-In-Time

Just in time (JIT) systems require a holistic approach to ensure accurate
production, ordering, and stock quantities to ensure that the right parts needed in an
assembly are available at the exact time they are needed and only in the amount
needed (Ohno, 1988). While this may seem intuitive, it can be difficult to create
such a system for a complex product where there may be many components and
subassemblies. Additionally, JIT systems are reliant on flexible internal and third
party component suppliers to cooperate with variability in ordering and delivery
agreements. This approach requires synchronization throughout the company and
transition from traditional "push" systems to a more flexible "pull" system. Push
systems utilize a central planning system to determine and dictate production
schedules, based upon sales forecasts, past sales records and customer orders. The
demand forecast is used by production control as the basis of how many components
to purchase, how much raw material to buy, at what rate to produce and when to
place orders (Ploss!, 1967).

A pull system regulates materials and production

through the withdrawal of only the necessary parts at the needed times from a
previous (upstream) process which has only produced enough units to replace the
parts that have been withdrawn. Company-wide JIT implementation results in the
elimination of unnecessary inventory thereby removing the need for warehouse and
storage space, while simultaneously decreasing inventory holding costs and
improving the ratio of capital turnover (Monden, 1998).

Organization wide

implementation of JIT can be difficult, but research has shown the positive impacts
of the system on other operational areas such as organization, human resources,
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quality

management,

information

systems,

technology

development,

and

manufacturing strategy (Matsui, 2006). This indicates a synergistic impact on a
highly linked system and an overall contribution to competitive performance
improvements.

2. 2. 5 Kanban
Kanban (sign board) is a communication tool to convey information about
picking up or receiving the production order (Ohno, 1988). Kanbans vary in form
(cards, bins, electronic signs, etc .... ) but they all circulate between the processes to
control the amount of production to ensure that only what is needed is produced.

Withdrawal Kanbans specify the type and amount of product required for the next
process to withdraw from the previous process, and a production-ordering Kanban
specifies the kind and quantity of product which the preceding process must produce
(Monden, 1998). This system is vital for a pull system to maintain just-in-time
manufacturing and prevent overproduction or underproduction of necessary
components. Figure 6 is a simplified example of the use of Kanbans to communicate
both withdrawal (retrieval) and production in the Toyota Production System®.
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Figure 5. Conceptual Diagram of the Kanban System (Toyota Motor Co.®)

While the Kanban system appears simple, it is important to realize that
understanding and calculating the optimal number of Kanbans required is difficult.
A system's robustness must be studied to gain an understanding of the future
environment where unexpected events such as breakdowns occur. If the Kanban
system is not optimized and flexible to handle variations, production will suffer and
the benefits of the just-in-time system will not be realized (Kleijen, 2003).
2.2.6 Kaizen

Kaizen (good change) was defined as continuing improvement in personal
life, home life, social life and working life. When this definition is applied to the
workplace, the kaizen philosophy is to create an environment of ongoing
improvement driven by company wide involvement at all levels (Imai, 1986). The
organization must create a sense of belonging to encourage employee commitment in
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order to facilitate the exchange of knowledge and ideas without fear of reprisal
(Recht, 1998). Continuous improvement requires a concerted effort to identify areas
of waste and propose solutions to those problems. Employees are encouraged to
make suggestions on a regular basis, and these suggestions create the basis for
continuous improvement.
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Figure 6. Comparison of innovation and Kaizen improvement (Imai, 1986)

Figure 6 compares innovation and Kaizen as complimentary means to
achieve improvement, the Y-axis of graph which is not shown, over time. The graph
uses a dashed line to represent Kaizen as continuous improvement, a vertical arrow
depicts the results of innovation or a Kaizen blitz, and the solid line, the new
standard, can be seen as a result of the combined effort of these actions. The term
innovation has evolved and is now known as a Kaizen event or a Kaizen blitz. The
focus of the event is to improve a specified process or area in a short time period,
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through the Kaizen ideals of company wide cooperation. One expert describes the
blitz as a week long event where a group composed of the process manager and
personnel outside the department analyzes the current state of the process or area of
focuses, address the problem, and implements the changes (Liker, 2004). By using
both approaches, continuous improvement can be sustained both short and long term.
"Ss" is a tool which can be used during a Kaizen event to reduce hidden
wastes in the plant through a cleanup activity, and is comprised of:
1. Sort- Organize and remove unnecessary materials.
2. Stabilize- Improve orderliness by designating proper spaces for everything.
3. Shine- Clean the area.
4. Standardize- Standards are clear and understood.

5. Sustain- Maintain the improvements and changes that have been made
(Allen, 2001 ).
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Figure 7.

Overview of areas of improvement and benefits of using SS (Hirano,

199S)
Figure 7 is an overview of direct and indirect benefits of Ss in the pursuit of
removing waste, defects and maintaining safe working conditions which is the
ultimate goal of lean manufacturing. SS improvements will result in: 1. Product
diversification. 2. Higher quality products. 3. Lower manufacturing costs. 4.
Reliable product deliveries. S. Improved worker safety and 6. Higher equipment
availability (Hirano, 199S).
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2.3 System Configurations
The statement "An hour lost at a bottleneck is an hour out of the entire
system" (Goldratt, 2004) embodies the "Theory of Constraints". It is essential to
identify a system' s bottlenecks and focus on improving them in order to realize the
full potential of the system. In order to address bottlenecks and meet customer
demands, manufacturers must be flexible, especially when changes occur with little
notice.
Machine configurations ranging from serial to hybrid to parallel have been
studied to determine their impacts on key metrics. Research investigating
performance was defined through the following metrics: productivity, quality,
convertibility and scalability to evaluate each configuration of equipment (MaierSperedelozzi, 2002). Findings indicated that a completely parallel configuration of
machines yielded the greatest performance improvements, with hybrid systems
yielding greater performance measurements than serial systems. While this work is
encouraging, parallel machining is not a "cure-all" approach, as research has also
shown that other configurations have their own advantages. Quality analysis has
shown that serial machining had the smallest standard deviation, and different hybrid
configurations had the smallest mean deviation and greatest convertibility (Zhong,
2000).

The complexity and needs of the system must be addressed for each

individual facility, equipment and product.

Additionally, the cost of parallel

machining must be considered, especially for equipment with long setup and change
over times.
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Z.4 Chapter Review
The basic concepts of selected lean manufacturing tools and other practices
used in outside industries were addressed in this chapter.

The overall goal of

manufacturing lean is the elimination of waste, as this principle is applicable to every
industry.

It is important to identify where practices are applicable in the

pharmaceutical industry.
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Chapter 3
3.0 Pharmaceutical Manufacturing Background

Chapter 3 will address the current state of pharmaceutical regulations by the
FDA through cGMP's.

This chapter will discuss Process Analytical Techniques

(PAT), a guidance approved in 2004, and regulations to improve innovation and
competitiveness, while giving examples of this technology currently in use.
Additionally, regulations regarding over the counter (OTC) products will be
discussed as an appealing area for advancing manufacturing based research. Finally,
opportunities for pharmaceutical manufacturers to take advantage of the new
regulations will be discussed.

3.1 Current State of Pharmaceutical Regulations for Manufacturing

Current pharmaceutical leaders have recognized the shortcomings of
cGMP' s; examples include dubious and repetitive product testing, validation
procedures and extensive documentation for well understood process changes.
Inflexible regulations have hindered process improvements in the past and became
the object of industry and FDA focus for change (Hussain, 2002). In response, the
FDA has recently released new Guidance for Industry which addresses the use of
PAT (FDA, 2004a) and Pharmaceutical cGMP's for the 21 51 century (FDA, 2004b).
These documents are supported by a number of cGMP ' s including: Q8 Guideline on
Pharmaceutical Development (FDA, 2006b), Q9 Guideline on Quality Risk
Management (FDA, 2006c) and QIO Guideline on Quality Systems which is still
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under development (Joneckis, 2006) to encourage innovation in the pharmaceutical
industry.
The FDA defines PAT as:
A scientific, risk-based framework intended to support innovation and efficiency in
phannaceutical development, manufacturing, and quality assurance. The framework is
founded on process understanding to facilitate innovation and risk-based regulatory decisions
by industry and the Agency. The framework has two components: (1) a set of scientific
principles and tools supporting innovation and (2) a strategy for regulatory implementation
that will accommodate innovation (FDA, 2004a).

The definition for PAT presented does not define the overall strategy of the
initiative, but serves as an introduction to the regulatory practice.

A practical

definition of PAT is given as "systems for continuous analysis and control of
manufacturing processes based on real-time measurements, or rapid measurements
during processing, of quality and performance attributes of raw and in-process
materials and processes to assure acceptable end product quality at the completion of
the process" (Hussain, 2002). These revised guidance documents have created a new
era for the pharmaceutical industry. The documents shift away from conventional
thinking, where process changes are discouraged due to the substantial financial and
scientific resources required to fulfill FDA documentation requirements. The new
focus is to understand the product, the manufacturing process, and operations. This
approach has been described as the "design space'', defined by the FDA as:
... the multidimensional combination and interaction of input variables and process
parameters that have been demonstrated to provide assurance of quality. Working within the
design space is not considered as a change. Movement out of the design space is considered
to be a change and would normally initiate a regulatory postapproval change process.
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Design space is proposed by the applicant and is subject to regulatory assessment and
approval (FDA, 2006a).

Within the design space, the control space has been described as a: "Multidimensional space that encompasses process operating parameters and component
quality measurements that assure process or product quality. It is a subset of the
design space" (Desai, 2006). Exploration and understanding of these areas will lead
to the identification of critical parameters, as well as metrics and methods to capture
their impact on the process, enabling quality management through a risk based
approach. A new control strategy aims to minimize risks associated with failures
when critical and non-critical process parameters fall outside the control space but
remain within the design space.
The FDA has recognized, similarly to outside industries, that quality must be
built into the design of the product, and that it cannot be achieved through testing or
inspection alone. Throughout the development and product life cycle, changes in
formulation and manufacturing practices offer opportunities to gain greater
knowledge of product characteristics and performance under various conditions.
Inclusion and analysis of all relevant experimental and experiential information can
be used to create, support, and expand the control and design spaces. While absolute
operational and process understanding is impossible, it is important to recognize
what is known and operate within those parameters. Figure 8 depicts a conceptual
representation of the importance of experimental data to provide the framework for
creating and supporting the control and design spaces as defined by the manufacturer
and approved by the FDA.
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Figure 8. Hierarchy of manufacturing control strategy (Low, 2006)

The FDA has given the pharmaceutical industry an opportunity to enter the

21st century of manufacturing by expanding the control space of their operations
while still staying within safe operating conditions in the design space. PAT has
excited many in the pharmaceutical industry, who see the potential to continuously
improve processes as they occur in other manufacturing industries.
This drastic change in the regulatory mindset has raised many questions
regarding feasibility and practicality. PAT has become an industry "buzzword" with
much of the knowledge only attainable through consultants, and/or is guarded
closely within the industry.

Current seminars and workshops address very specific

ideas of using novel techniques for limited areas, such as specific assays used during
processing to verify quality (Tyler, 2006).

Many consultants propose vague

"buzzword" laden approaches to improvements without scientific background and
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appear to be more oriented to selling their services. Adoption of PAT has been slow
due to a lack of technical knowledge and trepidation over regulations, as PAT is
currently only a guidance document and not a requirement.
PAT is still in its early stages of use, and there is wide spread skepticism and
uncertainty of how the FDA will regulate this new area.

While the long term

benefits of manufacturing improvements are clear, it is difficult to make the
argument for a sizable investment in innovation on a product currently being
developed for fear of clinical failure and the uncertainties of FDA product approvals.
Further, if a product will be approved, companies want to avoid delaying or
jeopardizing the approval process due to changes in manufacturing approaches.
Additionally, there are concerns over technological limitations, which prevent online
process monitoring and understanding for complex products such as protein drugs
(Glaser, 2006). Others have addressed some of these concerns in outside industries
and it is important to learn from their successes and failures.

3.2 Examples of Current PAT Use
Near infrared (NIR) spectrometry has been studied extensively for the use of
online monitoring of pharmaceutical products.

This non-invasive and non-

destructive technique has been studied for a number of different potential uses during
manufacturing. This method can identify and differentiate between differently
formulated products even if they appear identical, across a wide variety of dosage
forms (tablets, solutions, capsules, etc) (Medendorp, 2006). NIR has been studied
throughout the manufacturing process, from raw material qualification and
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quantification, in line monitoring processes and final packaging identification
systems.

Some monitoring applications

include moisture content, active

pharmaceutical ingredient (API) concentrations, blending homogeneity, coating
thickness and tablet hardness (Swarbick, 2006).
Raman spectroscopy utilizes an energy source, such as a laser or ultra violet

(UV) light, to excite molecules from their original states into an excited state, and
measures the vibrational level required for the shift (Raman, 1928). This tool has
been used in the identification, monitoring of homogeneity, and quantification of
different drug products. Polymorphs, defined as a drug substance existing as two or
more crystal chemical structures which may have different chemical and physical
properties than the original structure (FDA, 2002), have been identified as an
opportunity for processing improvements.

Continuous monitoring of polymorphic

transformation secondary to high sheer granulation in formulations for encapsulation
and the solubilization of API in inactive ingredients (excipients) has been studied
(Jayawickrama, 2006).

Raman probes have been placed in different machinery

during production to determine that this technique was viable for monitoring process
deviations, which negatively affect the product.

Monitoring and adjusting

processing to prevent undesirable polymorph formations through online Raman
monitoring to retain formulation homogeneity is an important tool for manufacturing
acceptable products (LaPlant, 2005). Currently, Raman and Infrared techniques are
limited to process monitoring but future developments should aim to incorporate
autonomation principles such as automatic processing adjustments when deviations
occur and automatic shut downs if adjustments do not solve the problem.
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There are a number of other methods of utilizing analytical and process
instrumentation to identify acceptable processing and product specifications. A few
examples are included here:

Mass spectroscopy has been proposed to monitor

moisture content of drug products during lyophilization to ensure acceptable
processing conditions to yield less than 1% water content (Wiggenhom, 2005). Cell
density probes have been utilized to monitor the fermentation process of protein
drugs, to reduce potential quality issues, process variability and meet the desired
target density with fewer deviations (Low, 2006).
Pharmaceutical manufacturing requires that strict processing and formulation
specifications must be met prior to the release of the product.

Currently,

manufacturers must "test in" quality by sampling a number of randomly selected
finished products prior to their release, known as end product testing. By monitoring
important metrics during production with a demonstrated correlation with end
product quality, one could conceivably avoid end product testing and utilize inprocess (parametric) release testing. In 1987, The FDA approved parametric release
only for terminally heat sterilized drug products. Parametric release is defined as "a
sterility release procedure based upon effective control,

monitoring, and

documentation of a validated sterilization process cycle in lieu of release based upon
end-product sterility testing. All parameters within the procedure must be met before
the lot is released (FDA, 1987)."

This regulation only applies to certain large

volume parenteral (LVP) products and requires a supplemental new drug application
for approval.

Currently several manufacturers have gained approval for parametric

release using moist heat sterilization (autoclave) methods, but it has not been adopted
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widely due to the extensive documentation and validation procedures required
(Stevens-Riley, 2005).

Chemical, ionic, and thermal methods of terminal

sterilization for many drug products to avoid end product sterility testing and allow
parametric release have been discussed by members of the United States
Pharmacopeia (USP) for FDA approval {Tirumalai, 2005).

3.3 Over-The-Counter Product Regulations
There are more than 100,000 over-the-counter (OTC) products and 800 active
ingredients, encompassing over 100 therapeutic classes currently for sale in the US
(FDA, 2000). There are two methods to get an OTC product on the market to sell to
the general public without a prescription. Similar to new prescription drugs, a New
Drug Application (NDA) for a specific product must be approved prior to marketing
which may require clinical studies, mandated FDA review timelines and postapproval maintenance (Christ!, 2006). An alternative method is to be in compliance
with an FDA approved drug monograph.

Monographs specify active ingredients

which must comply with standards that have been found "generally recognized as
safe and effective" (GRASE), and must comply with the monograph with regard to
the formulation, labeling, and testing requirements (FDA, 2006d). The United States
Pharmacopeial Convention is an independent volunteer organization recognized by
the FDA to set monograph standards for active and inactive pharmaceutical
ingredients, dosage forms, and medical devices (USP, 2007). Monograph products
do not require pre-approval or clinical trials; they have common labeling for all
similar drugs and are publicly available without exclusive marketing rights. The
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similarities between NDA and monograph products include:

safety and efficacy

standards, manufacturing and GMP inspections, labeling requirements and
advertising regulations (Hilfiker, 2006).
OTC monograph products represent an opportunity to investigate new
manufacturing techniques. Formulation, dosage form, concentration requirements
and labeling are the key monograph factors (Hilfiker, 2004), while manufacturing
processes are generally left to the manufacturers.

This flexibility allows

manufacturers to individualize specific processes to create their own version of the
product.

During the approval process for a prescription drug, clinical or

bioequivalence studies are required and the manufacturing processes used during this
period must remain the same after approval. If there is a significant change to the
production process, it must be validated and documented in a supplemental
document. The financial and time constraints cause pressure to gain an expedient
approval, and can later result in non optimal processes which are not changed for
fear of negative FDA action. As a manufacturing model, it would be more feasible
to use an OTC monograph product because it has been characterized and studied.
While monographed products still require validation for changes during
manufacturing, there is a greater flexibility and information available during the
initial production process planning.
3.4 Opportunities for Pharmaceutical Manufacturing

There is considerable opportunity to investigate the implementation of
current practices and knowledge found outside the pharmaceutical industry for
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incorporation into novel processes in line with the FDA's cGMP's and PAT
regulations.

The concept of the incorporation of external industries has been

proposed (Crosby, 2006), but research focused on these principles and their effects
on manufacturing operations and pharmaceutical product development has not been
explored. It is important to approach improvements to manufacturing while still
complying with cGMP and FDA regulations. Each product and manufacturer should
asses whether changes in their regulatory requirements are necessary if changes are
made.

3. 4.1 Batch vs. Continuous Processing
One of the most apparent areas that could be improved in the pharmaceutical
industry is a change from batch manufacturing to a continuous manufacturing
approach. Currently the metal industry has utilized continuous manufacturing for
metal matrix composite wires, among other products.

Originally the wire was

manufactured by batching, but long processing times and extended heat exposure
was detrimental to the final product. The process was redesigned addressing the
critical parameters required for a quality product, and thorough experimentation was
performed in order to identify the optimal operating parameters of the new process.
The new process yielded lower throughput times and lower exposure times which
had resulted in heat damage to the metal and an unacceptable product (Blucher,
2001).
Some areas of pharmaceutical production have considered continuous
production methods.

Tablet, transdermal patch and biotechnology product
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manufacturing have been studied to determine the potential advantages of continuous
manufacturing practices.

Granulation is a method to increase powder flow and

compressibility (Ansel, 1999), and is often a bottleneck in tablet manufacturing.
Some continuous production methods which have been considered to overcome this
problem include: fluid bed agglomeration, spray-drying, extrusion, instant
agglomeration, roller compaction and semi-continuous granulation.

Continuous

transdermal patch manufacturing using hot melt extrusion principles has been
studied (Wolff, 2000).

Spray drying techniques, used extensively in the dairy

industry, have been used in the biopharmaceutical industry but have been
increasingly displaced by lyophilization, a batch process. Ease of automation, lower
material handling, in-process controls, flexible manufacturing and avoidance of
scale-up are some advantages of a continuous system (Vervaet, 2005).

It is

important to consider that continuous practices are not a "one size fits all"
application, and individual products must be critically evaluated. This methodology
can be applied early on in the development phase, when considering formulations,
but it is critical to evaluate the formula's performance during the manufacturing
process, in vitro and in vivo.

If production .volumes are kept constant, continuous

manufacturing would require significantly smaller space and equipment, potentially
yielding a several fold cost reduction (Cini, 2006).
Currently there are technical and regulatory barriers which must be addressed
prior to the commercial institution of continuous manufacturing. Few manufacturing
systems can be easily adapted to a continuous process without significant capital
investment. Publications in this area are sparse, and narrowly focused on a single
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product, requiring expansive experimentation to gain the information required to
change. Additionally, some products are made in small quantities and production
goals can be met in a single batch. The FDA has given manufacturers theoretical
guidance, and the industry is unsure of the regulatory agent's interpretations of the
new documents. Manufacturers should not overlook previously discussed lean
techniques which could be evaluated and applied to the pharmaceutical industry now
for results in the near future.
3. 4. 2 Lean Techniques

Currently, setup times are very long for equipment and result in large batch
processing to preserve their economy of scale. The Toyota Single Minute Exchange
of Die (SMED) concept is focused on reducing the setup time for equipment which
had traditionally taken several hours to less than ten minutes.

This significant

accomplishment occurred through continuous improvement by employees at
Toyota®. Continuous improvements in setups in pharmaceutical companies could be
achieved utilizing shadow boarding, a visual control technique, which creates an
outline for mechanics tools and parts required for assembly of equipment, to ensure
that parts are not missing or incorrect. Currently, standard operating procedures
(SOP's) are required by the FDA, but may be unclear when compared to visual
controls used in many automotive manufacturing facilities. Standardized work and
error proofing techniques are aimed to aide manufacturers through simplification and
visualization of the process. While many SOP's may include sample graphs or
tables with information, they often do not utilize pictures or simple drawings to
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instruct the operator. SOP's can be technical and difficult to understand resulting in
operator deviations.

Simplification of the process, such as color coded setup

components, or creating one way assemblies of parts can simplify the setup and
change over tasks, while reducing the chance of an erroneous setup resulting in
damage to the machine or the product.
A pull system could be used to mcrease product flow through the
manufacturing facility and movement towards one piece flow.

Predominantly the

formulation aspect of pharmaceutical products requires a batch process to generate
the bulk drug. The following stages could utilize a semi continuous approach to
decrease batch sizes similar to Toyota® production method. Batch splitting or mini
batching could be explored to increase flow and flexibility in the remaining
operations. Kanban cards could be used to facilitate the pull system, especially since
the master batch record currently travels with the product throughout processing and
acts as a production Kanban. Retrieval Kanbans could be used to help create greater
visualization of where equipment and material should be placed to support the flow
of production.
3.4.3 Designfor Manufacturing
Design for Manufacturing (DfM) principles have been studied extensively for
products such as wiring harnesses, electronics, machining of metal components,
powder metal processing, plastic injection molding, sheet metalworking, casting, and
final assembly (Bralla, 1986; Boothroyd, 2002; Otto, 2001 ). There are opportunities
to develop similar principles for the development of drugs and medical device
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products. Traditional development methodologies are concerned only with creating
a safe and efficacious product. The product is then given to the manufacturing
department and is expected to be produced rapidly, despite the fact that
manufacturability was not considered at all during the design process. In reality, the
transition from development to manufacturing is a difficult and complex process.
Using principles from DfM to guide experimentation during formulation,
identification of factors that are critical to the manufacturability of the product will
support expansion of the design space to allow more flexible manufacturing.
Examples of experimental focal points include raw material properties, variation of
formulation characteristics and delivery device components.

3. 4. 4 Simulation

Simulation has been used throughout many industries to gain insight into
current conditions and hypothetical future states.

Mathematical models and

simulations have been used in operations research for many years to solve
operational, warehousing, transportation, distribution and logistical problems
(Chung, 2004).

Simulation has been expanded to address a wide array of

problematic areas for industries outside of manufacturing.

Lean manufacturing

principles have been studied to determine suitability for specific industries in order
to evaluate conceptual improvements that could be made through its implementation
(Abdulmalek and Rajgopal, 2007). By creating a value stream map as the foundation
of their simulation model, Abdulmalek and Rajgopal evaluated implementing lean
techniques to a steel manufacturer and determined which improvements were
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feasible. The simulation allowed the researchers to monitor WIP and production
lead time as their primary metrics, while creating a visual product for management to
encourage changes where needed.

3.4.5 Other Manufacturing Tools
Parallel and flexible machining could also be used in many of the processes
after the bulk drug has been formulated. Filling bulk product into its container,
cartoning of filled drug product and boxing of finished goods are all strong
candidates for parallel machining.

Utilizing flexible routing and reconfigurable

machines can reduce throughput time and minimize the effects of downtimes. Also,
resources required for production may be shared, and have a synergistic effect on
production rate and setup times.
Online and in line sensing methodology is continuously evolving and has the
potential to change the way processes are monitored.

Unfortunately the current

limitations are sensitivity issues and equipment can not accurately analyze all aspects
of the manufacturing processes. As the sensing and analytical technology improves,
manufacturers can rely greater on processing parameters and less on end product
tests.

3.5 Chapter Review

The current state of the regulatory influences guiding the pharmaceutical
industry was addressed in this chapter.

New guidance documentation and the

opportunities which have arisen for the industry were addressed. The opportunities
addressed may not apply to all pharmaceutical manufacturers, and it should be noted
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that there is varying commitment to lean manufacturing throughout the industry.
particularly small and medium companies with more limited resources may need to
explore these techniques.
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Chapter 4
4.0 Methodology and Procedures

Chapter four will describe the methods and procedures used to gam an
understanding of a product throughout the current system of the company used in
this study. Collected empirical data are defined as model inputs to accurately portray
the product in the system.

A simulation model will be employed to allow

visualization of the process and for identification of problematic areas. A theoretical
future state will be created in ProModel®software and compared against the original
current state to identify which changes to the system yield a significant impact.

4.1 Phase I - Current State of Pharmaceutical Manufacturing

Phase I will evaluate a manufacturing facility that produces pharmaceutical
products under current Good Manufacturing Practices to gain a "baseline"
understanding of current manufacturing systems.

This phase will develop a model

of the system to identify critical and problematic areas, to identify potential
opportunities for processing and formulation improvements.

4.1. 1 Evaluation of the Current System
The current manufacturing system will be evaluated by "walking the line"
and "gemba" (go and see) lean manufacturing techniques (Meier, 2001) to create an
accurate current Value Stream Map®. VSM inputs will include the collection of
direct measurements, historical data and empirical information. Manufacturing data
will be collected through direct and indirect methods, including time and motion
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studies and the measurement of factors such as Work In Process (WIP) throughout
the system, productivity, rework/scrap rates and other critical manufacturing
indicators (Hopp, 2001 ).

An AutoCAD® drawing of the layout will be used to

measure distances traveled by personnel and materials. Detailed employee shifts
with breaks will be collected to measure total work hours in a day. Delivery times
and quantities will be documented to monitor the flow of materials into and out of
the production facility.
Direct methods:
•

Measuring throughput time, cycle time and change over/setup times.

•

Counting materials, components, Work in Process (WIP) and finished
goods throughout the system.

•

Machine utilization/uptime and operators required.

•

Counting defects, rework and scrap rates.

Indirect Methods:
•

Quality Control Master Batch Records.

•

Other documentation recorded during the manufacturing process.

4.1.2 Simulation Modeling
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Figure 9. Simulation Overview (Sanchez, 2006)
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Figure 9 gives an overview of the steps required to create an accurate
simulation and how experimentation can be performed to gain insight into "real
world" problems in the current system. ProModel® software is a tool for simulating
and analyzing diverse production systems including assembly lines, transfer lines,
flexible manufacturing systems, job shops and Just-In Time systems. Resource
utilization, production capacity, efficiency, inventory levels, etc. are some of the
elements which can be modeled (PROMODEL, 2003). This software will allow
experimentation with numerous variables, such as equipment, personnel, and layout
with only conceptual alterations to the manufacturing facility. Data collected will be
analyzed to identify trends, which enhance production metrics, (throughput, Work in
Process, cycle time, etc.) (Hopp, 2001) and those that are detrimental to efficient
production. Simulation will allow visualization and will incorporate detailed
information about the system while closely conforming to the individual aspects,
(Askin, 1993) facilitating experimentation with theoretical scenarios to identify
problematic areas and potential failures. Phase one will result in the
characterization and creation of a simulation model of the existing manufacturing
system to identify the current manufacturing state.

4.1.3 Statistical Methods
In order to identify the most critical parameters after phase I, statistical
analysis will be used to determine factors of interest which will be tested during
phase II. A quality by design (QbD) method using a Box-Behnken design has been
recently employed by Zidan et al. (2006), and will serve as a model. Critical factors
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will be identified in phase I and ranked according to perceived impact and an
appropriate statistical design will be chosen based on the number and type of factors.
The top factors, approximately three or four, will then become the statistical focus of
the phase II simulation, with each of the factors containing appropriate levels for
thorough study.

Examples of potential critical areas include identification of

bottleneck workstations, problem areas (defect/scrap rates) and unreliable
operations/operators.

The significance of interactions between independent and

dependent factors will be evaluated through analysis of variance (ANOV A), with
graphs to enhancing visualization where appropriate (NIST, 2006).

Minitab®

Statistical software, Minitab Inc. Pennsylvania, USA (or equivalent) will be used for
all statistical analysis and generation of appropriate tables, graphs and charts.

4.2 Phase II - Future State of Pharmaceutical Manufacturing

Phase II will utilize the information gained in phase I to compare current drug
processing with a model of a theoretically and experimentally based "improved"
system. Improved systems will address the critical processing parameters identified
in phase one, and employ concepts adapted from alternative industries to gauge
feasibility and potential outcomes.

4.2.J Development of the Future State Model

To address the identified critical parameters, manufacturing tools from across
all industries will be utilized including The Toyota Production System®, flexible
manufacturing system designs, continuous processing methods, in-line product
testing and additional manufacturing tools.
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New processing and techniques for

manufacturing will be analyzed to determine feasibility, using simulation to
understand the impacts.

Experimentation comparing alternative layouts and

theoretical flexible systems to enhance production while potentially minimizing
space and expenses will be performed using simulation (Askin, 1993).
A design of experiment using a factorial design was chosen in order to
identify which interactions and factors achieve statistical significance.

Table 1

describes the 23 factorial design employed to compare the different simulation
models. There are three factors where the current state for each factor is denoted as
zero, and the future state is denoted as 1. Therefore, run 1 depicts the current state of
the system and run 8 is the most radically changed future state. In order to evaluate
which areas of the future state are significant, six other intermediate simulations will
be run, where some factors will be modified while others remain the same.
Table 1. Overview of Experimental Design
Factors
Scenarios

1
2
3
4
5
6
7
8

c

8

A

0
0
0
0
1
1
1
1

0
0
1
1
0
0
1
1

0
1
0
1
0
1
0
1

4.3 Chapter Review

This chapter describes the methodology that will be used to evaluate a
pharmaceutical manufacturer and a specific product.
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Using simulation and lean

tools, identification of problem areas and solutions will be evaluated. Additionally,
by using a statistical design, interactions between factors can be evaluated for

significance.
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Chapter 5
5.0 Case Study

Chapter five will describe a pharmaceutical company which was selected as a
case study for manufacturing improvements. The current manufacturing processes
of a product chosen as the focal point of the study will be described and evaluated.
A value stream map will guide the reader through the process and indicate where
value and non value added time is expended on the product. The data collected and
used to prepare the value stream map and the ProModel® simulation model will be
described in this chapter.

5.1 Background of the Pharmaceutical Company Selected for Study

The pharmaceutical company chosen for this study will be referred to as
XYZ Pharma in order to maintain their anonymity. While the company produces a
few proprietary and prescription products, it primarily serves as an OTC contract
manufacturer, producing over 100 human and veterinary products.

Management

currently describes that they are slightly behind schedule to meet customer deadlines,
but feel that they are one of the more reliable and capable contract manufacturers in
their market area.
5.1.J Facility

The facility has the capacity to produce oral products such as liquids and
suspensions, and topical products including gels, creams, liquids, adhesives and
more. This study will focus on issues affecting topical gels and their manufacturing.
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The company is comprised of a 25,000 sq./ft. production facility and a 75,000 sq./ft.
detached warehouse building, approximately 1/10th of a mile away. The production
facility layout can be seen in Appendix II, while the warehouse building, (not shown)
is not considered the primary area of study. Unlike many other manufacturers with
dedicated manufacturing equipment and personnel, XYZ Pharma is a self described
pharmaceutical "job-shop". At any given point they are manufacturing between five
and seven different products simultaneously throughout the production facility in
various formulation, filling and packaging areas. The company does not have a
yearly shut down period and strives to meet customer needs in a flexible and timely
manner.
Due to the high volume of products being manufactured and the need to meet
deadlines, the overall maintenance of the facility is lacking.

While there is an

employee dedicated to cleaning and waste removal, large amount of cardboard boxes
can be found throughout the facility.

Additionally, empty chemical containers,

usually 55 gallon drums, can be found in large numbers, 60-90 at any given time.
These barrels are removed by a recycling company which compensates XYZ Pharma
at an approximate rate of $2 per barrel.

Currently, the recycling company will

remove all unwanted drums at the request of XYZ Pharma, which occurs
occasionally every 10-14 days.

Materials waiting for recycling are stored in the

loading dock area, and often monopolize 75% of that area, creating obstructions
during loading and unloading of trucks. Material handlers must frequently move raw
materials and finished goods multiple times to access blocked pallets.
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5. J. 2 Personnel

There are approximately 55 employees. Many employees are temporary, but
permanent employees have between 5 and 15 years of experience at their position.
There are three overlapping shifts: shift 1 starts at 5:00am and ends at 2:00pm, shift
2 begins at 7:30am and ends at 4:00pm, and shift 3 begins at 2:00pm and ends at
10:30pm. Each shift is entitled to two 15 minute breaks and a 30 minute lunch
period.

There are currently two mechanics who service all of the filling and

packaging lines in the facility, with a third mechanic in training. Two manufacturing
specialists formulate all topical products.

There is currently one "dishwasher"

responsible for sanitizing parts and components for equipment, but he feels there is
need for another full time washer.

Two material handlers move most of the

components and trash in the facility, but often assist in other areas when needed.
There are between 20 and 30 operators during the shifts to run the filling and
packaging machines. Only a select group of operators have been trained on the
newest filling machine, and their operating times are limited to the second shift
(7:30am - 4:00 pm). During slow periods, operators build inventories of boxes or
they are sent home. There is currently a surplus of operators, who are occasionally
given time off due to lack of work.
5.1.3 Quality Control

The quality control (QC) department functions to ensure that all shipments
received and products exiting the plant meet quality specifications.

The QC

department consists of a laboratory based group with five analysts. All incoming raw
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chemical ingredients and packaging materials must be placed into a "quarantine"
area. This designation identifies that the materials have not been tested to ensure that
they meet the required specifications. A QC analyst must sample the quarantined
material and upon successful testing, the material is released to the general
production warehouse area or production facility.

Raw materials will generally

spend between one and two weeks under quarantine before they are released for use.
This group is also responsible for all analytical testing of the bulk formulated drug
substance, the final product filled into packaging and stability studies required to
determine expiry periods.
The other function of the QC department is the monitoring of all
manufacturing operations and documentation. This section of the QC department is
comprised of 6 inspectors and a supervisor.

There are 12 total QC employees

responsible for ensuring quality and proper documentation at XYZ Pharma.
Inspectors rotate around the facility to monitor a number of processes at once and
must record their findings in the master batch record.

The master batch record

captures manufacturing and formulation data and is vital for the manufacturer to
prove to the FDA that all SOP's, and cGMP's were followed. All equipment must
be inspected by QC prior to machine setups to ensure that proper cleaning has
occurred and there are no residual materials on the parts.

To ensure proper

formulation, QC is required to initial the batch record along with the manufacturing
specialist after every step in the process. Tube filling is monitored by checking the
weight of 5 tubes every half hour to ensure accurate fill weights. Filled tubes placed
into cartons must be inspected every half hour to ensure the machine is producing a
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legible lot number and expiration date on the cartons. This monitoring is in addition
to visual and weight measurements taken by the operators and supervisors to make
adjustments to the machines on a regular basis, approximately every 15 minutes.
Finally, it is the responsibility of a separate dedicated QC inspector to reconcile all of
the batches manufactured. Finished goods are considered to be quarantined again
until the product has been fully tested and the shipping release has been completed,
which may take up to a day or two.

All packaging components, raw materials,

defects and finished goods must be counted. All of the inventory must be accounted
for and finished goods production must be within 10% of the desired goal. The QC
supervisor then must compile the master batch record with the reconciliation
documents and acceptable test results from the QC laboratory group's quality tests.
When all of these documents are compiled, the shipping release sheet is created and
signed by the supervisor in compliance with FDA regulations. The batch is then
released, removed from the quarantine area and ready to be shipped out to the
customer.

5.1.4 Deliveries

One driver is responsible for operating and filling XYZ Pharma's truck,
which travels between the main warehouse building and the production warehouse
area in the production facility with raw materials, finished goods and recyclables. If
material handlers are available, they will assist the driver in loading or unloading the
truck. The truck is on a continuous delivery schedule beginning at 7:30am and
ending at 4:00pm. Occasionally, the truck will make deliveries or pickup materials
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from an outside company and material will buildup in both buildings. The truck
completes one trip where it is loaded and unloaded between the two buildings in one
and half to two hours. These milk runs create a steady flow of materials entering and
exiting the system. Currently, the truck is not always filled before it departs from the
production facility loading dock.

Poorly marked components for return or the

unknown status of a finished good prevents the driver from independently making
return decisions. If cardboard is to be recycled, it will be taken to the warehouse if
the pallet has been wrapped by the pallet wrapper and placed in the loading dock or
storage facility, but the driver will not actively search for additional return materials.
Instead, a warehouse supervisor must instruct the driver what to remove.
Additionally, the last truck load at 4:00pm leaving the production facility is empty
and stored at the warehouse building's loading area.
The external shipping truck, operated by a freight company, arrives at the
warehouse production area daily between 1:OOpm and 3:30pm, and serves to ship
finished goods inventory or deliver small packages of raw materials. Small packages
of raw materials are generally less than 5Kg and are stored in a designated area of
the production building for easy access by manufacturing specialists during
formulation. Large quantities of incoming materials from the external shipper arrive
at the warehouse building daily. Outgoing shipments of large finished good orders
are removed to the warehouse building as well, where there is ample storage room to
organize and store the order.

Lead times for raw materials vary, with readily

available chemicals arriving daily with a 1-2 week lead time. This is in stark contrast
to custom printed plastic tubes and packaging materials which arrive once every 4
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months due to their long lead times of 8-12 weeks. Long lead times for materials,
coupled with time spent in quarantine results in XYZ Pharma holding a large amount
of raw materials inventory in order to meet variable customer demand.

5.2 Current State for Manufacturing of Product X

This study will evaluate the manufacturing of a poloxamer based topical gel,
referred to as product X, sold in a one ounce tube with an average yearly production
of 120,000 tubes per year, produced in 30,000 tube batch sizes as requested by the
customer.

This product is similar in formulation and manufacturing processes too

many other products manufactured at XYZ Pharma and is representative of the
system.
Production schedules are generally made weekly in response to customer
purchase orders, but last minute changes occur if customer deadlines are missed or
the order is changed.

In response to the schedule, a material requisition and a

packaging requisition are sent to the production warehouse area where raw chemical
ingredients and packaging components, such as tubes and cardboard boxes, are
primarily stored.

The materials requisition indicates the type and quantity of

chemicals that are required for the formulation of the product.

The packaging

requisition indicates the type and quantity of components required to package the
formulated material. All ingredients and components are held in quarantine until
verified by quality control (QC) through an identification assay to ensure identity
and potency, or compliance with specification limits for components. The individual
components are weighed and product is then formulated by a manufacturing
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specialist and filled into a large storage vessel. Unused raw materials that are no
longer needed for formulation are returned to the production warehouse area, where
they are returned to the main warehouse building. Theoretically, a sample of the
bulk formulated product from the vessel should be assayed before filling into tubes.
However, the bulk is often assayed by QC at a later time, while the product is filled
into tubes and concurrently undergoing end product QC testing of finished goods.
The vessel may be taken to the filling machines for immediate tube filling but is
more commonly stored until a machine is available. The vat is then moved to the
filling machine, where tubes are filled and crimp sealed. The filled tubes are stored
near the cartoning machine or intermediate manufacturing holding area until the
batch is finished or nearing completion. The manufacturing process has undergone a
validation procedure, which requires only one tube selected at random to be tested by
QC for end product release testing. The tubes are then loaded into cardboard cartons
and filled into boxes with preprinted company labels. Filled boxes are loaded onto
pallets and wrapped in protective plastic, before being moved to a quarantine area.
After all QC assays, reconciliation, and necessary documentation are complete, a
shipping release form is completed and the product is ready to be shipped to the
customer. A schematic overview of the process and the material flow through the
buildings in which they take place can be seen in figure 10.
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Figure 10. Material Flow Chart
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5.2.1 Formulation of Product X
Prior to formulation, all equipment, parts, and the manufacturing area must
be inspected and documented for cleanliness by the QC department. ., Visual and
smell tests have been validated with chemical analysis support to identify residual
materials from previous batches. Upon QC's approval, equipment setup begins and
the manufacturing specialist assembles the machinery for use depending on the
product to be produced.

The manufacturing specialist is responsible for all

fonnulation equipment and other materials such as pumps, tubes, etc. There is one
equipment washer who works during the second shift and is responsible for cleaning
the machine parts. When he is not working, or if the cleaner is overwhelmed, the
manufacturing specialist must clean the parts needed for setup. This may result in
used kettles left over night, or weekends until the manufacturer is available to clean
the area.
Product X is comprised of six ingredients which are brought from the
warehouse, while deionized water is hard piped and validated for purity to meet
necessary standards into the manufacturing area. Chemicals are stored outside of the
manufacturing area, if space is available, or held in the production warehouse area.
Each ingredient must be weighed, checked, and then documented to be accurate by
both the QC inspector and the manufacturing specialist. The ingredients are then
added in a four phase approach to ensure a pharmaceutically elegant and accurate
product. Empty drums are taken to the cleaning area by the manufacturing specialist
during production to keep the manufacturing area clear.
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Excess raw chemical

ingredients are placed outside of the manufacturing area for return to the warehouse,
or future use.
Product X is formulated in a 1000 L capacity Lee Kettle® equipped with a
sweep mixer and a built in Toledo® scale. A smaller 300 L Hubert® mixing vat is
used for high shear mixing and solubilization of material prior to transfer with an air
pump into the Lee Kettle®. The product undergoes a 23 step formulation process,
which is described specifically in the Master Batch Record and that can be
categorized as weighing and addition of ingredients, mixing, heating, milling,
material transfers and de-aeration (settling). During the production period, the QC
inspector periodically checks on the manufacturing specialist dependent on which
step he is performing to verify his work and sign the master batch record. The
product is completed when it has been entirely transferred into a stainless steel
storage vat through a milling process. Table 2 gives the data collected through time
studies. The value added time has been identified and serves as the basis for the
calculations of the formulation kettle's uptime.
Table 2. Data of Formulation Time for Batch #2

Formulation

10:21
10:45
10:48

Action
Chan_g_e Over
Start
StoR
Start

11:09 StoR
11 :15 Start
12:19 StoR
1:00 Start
1:25 StoR
1:30 Start
1:55 StOR

Non Value
Added
J_Minj
662

Value
Added
j_Minl

24
3

Went to_g_et Scale

21
Went to Dispensory for
Chemical

6
56
41

Lunch

25
Waitin_g_ for QC

5
25

Went to _g_et ScooRer

57

4

1:59
5:17

Start
Sto_.E_

198
120
469

Millin_g_ Transfer

721

Total

5.2.2 Filling of Product X
A mechanic is responsible for the setup of the filling equipment and must
have a QC inspector check all of the parts for cleanliness prior to setup of the
machine. The mechanic performs the machine setup, and must prime the machine
with product to make adjustments and ensure accurate filling within specifications.
Product X is filled into the hopper from the storage vessel using a transfer pump.
Common adjustment issues include misfed tubes due to incorrect carousel or loader
settings, inaccurate fill amounts requiring adjustments to the filling mechanism, poor
crimp seal due to inaccurate heights of the tube holder or dirty crimping surfaces and
tubes jamming.
The company currently has two different types of tube filling machines; they
have three older Kalex® machines and one new IWKA® Packaging system. Product
X has been manufactured on both types of machines on separate occasions. The
Kalex® machines have been used extensively for many years in the plant and the
majority of employees are trained on the machines which can be run on all three
shifts with only minor adjustments after the initial setup. Additionally, the Kalex®
machines are less complex than the new IWKA® machine and can be setup faster by
the mechanics. The new IWKA®system is only run by a select number of operators
and generally runs during the 7:30am to 4:00pm shift, but will run longer to meet a
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deadline if the operators are available.

The Kalex® machines are capable of

producing 35 tubes per minute of product X using two to three operators.

The

1WKA® system can produce 70 tubes per minute using between two and four
operators. Data collected during the filling of product X is presented in table 3, with
both value added and non-value added time.

Table 3. Data for Tube Filling Batch #3
Tube
Fillin_g_

Value Added
_{_Minl

Action
Chan_g_e Over

IWKA

Non Value
Added_{_Minl
300

8:45
9:30
9:50
9:55
10:00
10:02
10:03
10:08
10:12

Start
Break
Start
Sto_Q
Start
Sto_e_
Start

Mechanic adlust

Stop_

Tube Loadin_g_

10:13
10:14
10:15
10:16
10:23
10:26
10:45
10:47
10:48
10:50
11 :01
11 :08
11 :1 2
11 :1 9
11:53
12:00
12:30
12:42
12:50
2:37

Sto_e_
Start
Sto_2._
Start
Sto_£
Start
Sto_J.)_
Start
Sto_£
Start
Sto_Q
Start
Sto_Q_
Start
Sto_Q_
Lunch
Start
Sto_Q_
Start
Sto_2._

45
20
5
5
2

Cleanin_g_

1
5
4

Start

1

Not Sealing
Pro_Q_er!Y_

1
1

Adiustments

1
7

Fill Adlustments

3
19

Cleaning_

2
1

Fill Aqj_ustments

2
11
7

Aqj_ustments
4

Crim_£ Defects

7
34
7
30

Cleanin_g_
12

8

Ho__i:>_Q_er Overflow
107

Cleanin_g_

3
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2:40
2:55
3:57
4:00
4:12
4:19
4:20
6:40

Break
Start
StoR
Break
Start
StOR
Start
StqQ_

15
58

Cleanin_g_

3
12
7

Jam

1
80
399

Job Com_E!ete
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Regardless of the filling machine used, a QC inspector must monitor the fill
weights of five random tubes every half hour. A calibrated balance is kept within six
feet of the filling machine and is used to weigh the tubes. If one of the tubes does
not meet the weight specification, there must be an adjustment and five more tubes
are tested. If tubes are not able to be brought into specifications, the machine is
stopped for further adjustments and testing. Tubes manufactured during this time are
weighed individually to determine if they are within specification, if they fall outside
of a +/- 10% range, they must be rejected. This in-process testing aims to minimize
the number of out of specification products that are produced. Although this system
is relatively crude and does not adhere to statistical process control ideas, it does give
QC an indication of gross errors.
Operators are responsible for loading empty tubes into the chamber to ensure
a continuous supply of tubes for filling. The hopper is fed with formulated material
by operators periodically adding the bulk drug through the transfer pump from the
storage vat.

The hopper has been overfilled by accident, especially when the

machine is run with fewer operators. This error requires operator cleanup, machine
shutdown and wasted bulk product.
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After tubes are filled and crimp sealed they are ejected from the machine and
inspected by operators. Each tube must be squeeze tested and visually inspected to
ensure a visible lot number and expiration date. If a tube fails either of these criteria
it is thrown into a rejection tote which generally consists of <l % of total production.

If the tube passes the inspection criteria, it is put into a plastic storage tote on a
pallet.
Each pallet holds up to 20 plastic totes, and the company owns 52 totes.
When the totes are full, boxes are assembled (boxes are later reused for other
products) by operators and filled in place of totes if the next process, cartoning, is not
yet running. This occurs when the slower machine is used because the cartoner runs
at a significantly higher rate and they want to prevent machine starvation. Therefore,
the batch is completed to build up inventory and stored near the cartoning machine
until it is ready to be cartoned. In contrast, they have overlapped the IWKA®and the
cartoning machine with a buildup of approximately 6,000-8,000 tubes of WIP and
were able to reuse totes and avoid using cardboard boxes for WIP storage.

5.2.3 Cartoning of Product X

A mechanic must setup and adjust the Jones® cartoner to accommodate the
size of the carton, the feed rate of cartons into the machine and the tape machine (a
subsystem of the Jones® cartoner) to fit the different cardboard box sizes.
Additionally, the mechanic must setup the machine to produce an accurate and
visible lot number and expiration date. A QC inspector must check and document
that the lot number and expiration date is correct and visible prior to beginning
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cartoning.

Before production begins, three to four operators assemble large

quantities of preprinted cardboard boxes which are readily available to be filled with
cartoned product.
Cartoning occurs at a load rate of 78-82 cartons per minute. The machine can
operate through all three shifts and run with between six and eight operators.
Cartons are manually loaded by the supervisor into the feeder, which then is
automatically loaded onto a conveyor which opens the carton. The opened carton
travels around a circular track and two or three operators manually drop filled tubes
of product into the open cartons. The filled cartons are then closed while in the
cartoner and collected into groups of six after exiting the machine by an operator.
The groups of cartons are then covered in plastic by a Shanklin® seal wrapper
machine by an operator before being sent through the Clamco® heat sealer. An
operator fills the plastic sealed packs into cardboard boxes, which are then sealed
with a 3M® taping machine. Taped boxes are placed on pallets and taken to the
Lantech® pallet wrapper. Finished goods are placed in the production holding area
under quarantine to await final assay results and reconciliation of quantities. The
product may be moved via an internal shipping truck to the warehouse facility to
await final shipping release if the QC operator has documented the quantity
produced. Time studies collected during cartoning of product X is presented in table
4, with value added and non value added time described.
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Table 4. Jones Cartoner Data Collection for Batch #3
Value
J_Min)_

Carton er
Chan_ge Over
Building Boxes

4:20
4:28
4:30
5:01
5:03
5:25
5:26
5:40
5:46
7:00
7:30
8:12
8:14
9:00
9:15
9:37
9:40
10:15
Next
DC!l,
5:45
7:30
7:45
8:45
Total

Catchin_g u_Q

St~

Ac!i_ustments

Start
Stop
Start
StoQ_

Added

2
31

Start
St~

Non Value
J_Min)_
240
120

8

Start
Sto_I>_
Start

Start
Stop
Start
Sto_I>_
Start
Sto_Q_
Start
Sto_Q_
Start
Sto_Q_
Start
Sto_I>_

Added

2
22

Catchin_g l!2.

1
14

Fixing

6
74

Dinner

30
42

Adjustments

2
46

Break

15
22
3

Fixing
For NJg_ht

35

75
15

Break
Job Complete

60
454

436

5.2.4 Current State Value Stream Map

Data for the current state map of the system for product X at XYZ Pharma
was collected through time studies and is presented in Tables 1 through 4.
Additional data was retrieved from the master batch records of four recent
production runs of Product X, as shown as in table 5. Uptime percentage was
calculated by dividing the value added time (of the batch) by total production time,

63

both value and non value added. Non value added time was comprised of breaks,
lunch, machine breakdowns and setup/change over times. Table 5 compiles data
from four batches of product X. The batches of the first two columns were filled
with the slower filling machine and waiting times designated as **, were not
included because they are not accurate representations of the system when the newer
machines are used. Additionally, one of data points for vat storage designated as *,
was not included because it was unusually long.
Table 5. Overview of Batch Records of Product X

Batches
Formulation/mill
Time
Storage in Vat
Filling Time
Scrap
Filling
(%)
Waiting
Time
for Carton
Cartoning Time
Cartoning Scrap
(o/~

Wait Time To
shiQping
Total (Min)
Total (Hrs)

Kai ex

Kai ex

IWKA

IWKA

1

2

3

4

520
524
11805* 1110
998
1055

505
4965
525

535
3945
465

0.2

1.9

0.9

3.2

**
545

**
530

360
470

150
480

148.5
255
506.25 36.8

1.64

0.6

0.5

0.3

0.76

900
4121
68.68

3330
10,156
169.27

2715
2315
8294
7433
138.23 123.88

AVG

Std Dev

521
3340
495

12.4
1997.4
308.7
1.3

0.6
1263.4

The current state value map, shown in figure 11, gives the cycle time (CT) of
an individual tube through processing, except during formulation where the batch is
undergoing value added work at the same time. The map shows that the greatest
wastes of time are the buildup of WIP in the systems before the filling line and after
the cartoning process, where finished goods pallets are stored until the entire batch is
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complete and ready for shipment. The lead time of the system was calculated to be
7925 min and 50 sec. When divided by the total amount of operational hours from
5:00am to 10:30pm (17.5 hours) the lead time is roughly 7.5 days. The current state
is based on a five day work week, with Saturday and Sunday as days off. This
translates into a "real world" lead time of 9.5 calendar days for one batch. An order
for this product generally consists of three batches requiring minimal inter-batch
changes, resulting in decreased holding times to avoid starving down process
machines. Therefore the second and third batches are produced faster, and the entire
three batch process requires approximately 11 days of processing or 15 calendar
days.
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Figure 11. Current State Value Stream Map
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5.3 Development of the Pro Model® Simulation of Current State

The ProModel® simulation utilizes collected data presented m tables 1
through 4 and compiled master batch records, table 5, to create a model which
depicts the current state of the system. All processing times, waiting times, and
personnel assignments have been created through observation and verified through
company documentation. A full text version of the model can be found in Appendix
III. Figure 12 shows the layout of the facility and where the locations have been
built. The flow of materials follows the current stream value map in figure 11 and
the schematic material flow in figure 10.
5.3.1. Current State Model Assumptions
1. 1st

shift

(5 :OOam

-

2:00pm)

is

comprised

of

operator_ I

and

material- handler- I.
2. 2nd shift (7:30am- 4:00pm) is comprised of the manufacturer, mechanic,
driver and operator.
3. 3rd

Shift

(2:00pm-

10:30pm)

is

comprised

of

operator_2

and

material- handler- 2.
4. The Truck Driver has the sole responsibility of (un)loading the truck.
5. Shipments of raw ingredients arrive on one truck and are of sufficient
quantity to manufacture three batches for a total of 30,000 tubes of Product

x.
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6. Raw ingredients are taken directly to the manufacturing area, excess is first
stored in the formulation holding area and the remainder is kept in the
production warehouse area.
7. Each batch of formulated bulk requires 2 pallets of Raw_Ingredients_Drum
and 2 pallets of Raw_Boxed_Ingredients to be combined.
8. After a batch of formulated bulk drug has been removed, the manufacturer
immediately begins the next batch without a setup, until all batches have been
formulated.
9. Mechanic setups of the filling machine begin after the stored bulk drug vessel
has been brought to the filling area.
10. Filling using the IWKA® machine is completed by the "operator", which
consists of three operators specially trained on the machine who only work
during the second shift (7:30am - 4:00pm).
11. The filling machine fills 84 WIP totes, which contain 375 tubes per tote to
account for a small batch overage.
12. Mechanic setups of the cartoning machine begins after the entire batch of
tubes has been filled into WIP totes and moved to the Jones®WIP feed area.
13. The Jones® cartoner can be run by either operator_! or operator_2 which
both consist of 7 operators each and operate in the first and third shifts
respectively.
14. Finished goods are packed into 72 count boxes before they are palletized as
70 boxes to a pallet.
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15. Material handling is performed by one material handler during the first shift
and a designated material handler during the second shift which is normally
an operator or supervisor.
16. Each completed batch yields 6 pallets of finished goods inventory. When 6
batches are completed, the QC reconciliation process begins prior to
shipping.
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Figure 12. Current State ProModel® Simulation Layout
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5.4 Chapter Review
This chapter introduced XYZ Pharma as a manufacturer and described the
system required to produce Product X. Data collected through time studies and
master batch records were presented to give the reader an understanding of how the
product is currently manufactured.

The current stream value map helped in the

identification of problematic areas throughout the system. The results of the current
and altered future state ProModel® simulations are presented in the next chapter.
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Chapter 6

6.0 Results

This chapter will present possible areas for improvement to the current
system based on the ProModel®simulation and current stream value map. Three of
these areas for improvement are modeled in a future state. The primary study,
metric, that was chosen, was the minimization of throughput time to improve
meeting deadlines for contract customers.

The results of these future state

simulations were analyzed for statistically significant factors and interactions.
6.1 Results of the Current State ProModel®Simulation

The data tables presented are separated into two groups: inventory and
transfer holding locations and equipment locations. The equipment locations are
areas that processing of WIP occurs, while the inventory and transfer holding
locations are all of the supporting locations for the manufacturing systems. Table 6
shows the results of the current state simulation to gain an understanding of the
steady state of the system.

Unlike the value stream map, the simulation runs

overnight and on the weekends, to describe a more realistic picture. The calculated
average throughput time through the system for 999 replications of the simulation
was 370.92 hours or 15.45 days. In order to ensure that the simulation adequately
represented the real world conditions the average time per batch, 123.88 hours (from
table 5), is multiplied by three to give a total order time of 371.65 hours. The
average time from the simulations is divided by the average time from the master
batch records and is 99.8% similar. It is important to consider that time value is
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averaged and does not account for overlapping production of batches which may
occur.
The IWKA® filling machine has the highest percent utilization of processing
equipment while the pallet wrapper has the lowest. The largest periods of non value
added time are when the operation waits to batch. The time the formulated bulk drug
product spends in the transfer vat waiting to be brought to the filling line is very
long. Also the time spent waiting for the batch of wrapped and palletized finished
goods is considerable. Due to the infinite capacity of the production warehouse area
in the model, the utilization percent is not calculated, this was purposely avoided to
prevent blockage of incoming, outgoing and stored materials which would require a
separate in depth material handling study out of this project's scope.
Table 6. Results of the Current State ProModel® Simulation
Location Name

Inventory
Holdif!K

Transfer

Avg Time Per Entry (MIN) % Utilization

and

Production Warehouse Area
Formulation Holdin__g_ Area
Storage Vat Load
Vat Holdin_g Area
IWKA WIP Holding
Jones WIP feed
Jones FGI

3081.99
934.16
977.77
7097.92
54.86
353.97
203.02

0
12.79
13.39
31.64
0.64
4.06
14.32

1397.93
1816.03
142.85
27.14

19.14
24.58
16.49
2.26

E.!l_uipment
Lee Kettle
IWKA
Jones Cartoner
Pallet Wr'!££er

Total System Throughput
Time
370.92 hrs
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15.45 days

The average time per entry (min), is the average time an entry spends at a
location.

The utilization percentage is defined as the percentage of capacity

occupied. The utilization percentages appear lower than the uptime calculated by
hand for the current stream map because physical capacities were not always fixed or
clearly defined. The simulation calculates utilization over the course of the entire
run and is different from the value stream map which calculated the uptime for each
machine to process the first unit of the product. For the production warehouse area
an infinite capacity was assigned to prevent the blockage of incoming or outgoing
material; therefore, there is no calculation of the utilization %.
Table 6 shows that the two highest utilization percentages of equipment or
inventory transfer and holding are the vat holding area and the IWKA® filling
machine, respectively. These areas appear to be bottlenecks in the current system
and should be viewed as areas for improvement for the future state. While the
production warehouse area does not have a calculated utilization percent, the average
time per entry is the second highest and should also be considered as a potential area
for improvement.

6.2 Areas for Improvement

All of the areas for improvement suggestions considered in this paper are
from an efficiency approach.

cGMP's must be followed for each product and

manufacturer considering changes. Experimentation and validation may be required
to implement the proposed changes. The FDA and appropriate regulatory documents
should always be consulted if there is uncertainty in a regulatory area.
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6.2.1 Quality Control
6.2.1.l Testing
Testing bulk at the same time as finished goods is double end product testing.
This is a common practice where management is confident that its process will result
in an accurate product because it has been rigorously validated, but it does leave the
company vulnerable if the assay fails because many tubes have already been filled by
this point.

A bulk drug product can be "reworked" to meet specifications if a

deviation report is filed, but once the product is filled and crimped into tubes, it is far
too labor intensive and cost prohibitive to empty each one for rework.

6.2.1.2 JIT QC
The quality control department is responsible for reconciling (counting) all
materials that have been used, defects produced and finished goods for release. The
majority of finished goods may not be released from "quarantine" until the product
has successfully passed shipping release testing for quality and QC reconciliation to
meet FDA requirements. Finished goods can be shipped under "quarantine" if the
reconciliation documents have been completed for the materials shipped and a
sample has been taken for testing.

Upon successful testing of the product, the

customer is faxed confirmation of the test results and the product is removed from
"quarantine." This practice would shorten lead times and could be considered for
low risk products to ensure that a batch is not defective. Often the QC inspector will
wait until the entire batch is completed before counting the finished goods inventory
and compiling the final batch release documentation. Due to space limitations in the
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production facility warehouse, quarantined finished goods may be moved to the
larger

warehouse

building

until

they

pass

shipping

release

parameters.

Unfortunately, the QC inspector is often unaware if a pallet of quarantined finished
goods has been moved to the other building and can cause delays and errors during
reconciliation.

Conversely, if the inspector does count a portion of the finished

goods and they are available to be moved to the main warehouse, it will not be
moved by the material handlers unless the warehouse supervisor instructs them. By
having the QC inspector keep an ongoing count of finished goods pallets as they are
produced and placing a marking such as a neon sticker onto the pallets, the material
handlers will know to put the pallets on the milk run truck. This will free up space in
the production warehouse area and decrease the time required for reconciliation after
production is complete.

6. 2. 2 Deliveries
"Milk-Run" Truck Efficiency Improvement
Currently the "milk run" truck runs between buildings approximately every
one and a half to two hours. The truck is not always full, and leaves the production
facility empty on its last run at 4:00pm. This is surprising considering the production
building warehouse is normally very congested and items are usually blocking each
other.

Cardboard generated during manufacturing can be found throughout the

facility and is only removed occasionally. Excess raw ingredients and components
often stay in the production warehouse area for a few days after they could have been
removed. By utilizing the proposed QC improvements above, the truck will have
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excess material to load throughout the day and can fill the truck more often. Storing
the truck at the production facility overnight will allow late shift employees to place
materials directly into the truck and avoid the production warehouse area completely.

6.2.3 Inventories
6.2.3 .l Decreasing Storage Vessel Batch Sizes
The steps involved in the formulation of bulk drug can not easily be changed,
as the process has been given by the customer and validated by XYZ Pharma. A
significant change in the formulation would require revalidating the process for the
FDA. This product is relatively complex and requires many processing steps, many
of which have been developed with current batching equipment in mind. Until
development of continuous formulation methods and equipment improve, the
product is not currently a strong candidate to make the transition from batching.
However, after the bulk drug has been formulated, there are opportunities to decrease
the batch sizes of the WIP in the system. Currently, all 877 Kg of the bulk drug is
milled directly from the Lee Kettle® to a large stainless steel transfer vat. This
process takes an average of two hours and the transfer vat is then available for the
mechanic to prime the next process, the filling machine and complete the setup
process. The transfer vat is on wheels and is moved by the manufacturing specialist
to the storage area while the mechanic moves the transfer vat to the filling machine
and must be carefully navigated through the production facility. The stainless steel
transfer vat could be replaced with four 55 gallon drums, fitted with a non reactive
plastic liner validated to avoid chemical reactivity and degradation. The drums have
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capacities of 225 Kg each which would allow the mechanic could complete the
filling machine's setup, and begin filling an hour and a half sooner. Each drum
would contain approximately 25% of the quantity of the transfer vat, and could be
filled in half an hour. The drums are individually transported with a drum dolly by
material handlers or the mechanic and are more maneuverable, occupying far less
floor space than the transfer vat.

The viscosity of product X allows direct transfer

from the drum to the hopper via a compressed air pump and would free up a transfer
vat, which are often in short supply.

6.2.3.2 Decreasing WIP Buffers
Currently tubes are filled with product X and then put into plastic totes.
Totes contain an average of 375 tubes and are stacked 20 totes to a pallet. Full
pallets are then removed from the filling area and are stored near the next machine,
the cartoner.

The cartoner is not started until filling is complete or very near

completion. This buildup in WIP is in response to the cartoner running slightly
faster than the filling machine.

The cartoner loads 80 cartons per minute, each

carton is filled with one tube of product X, while the IWKA® filling machine loads
70 tubes per minute. The filling machine generates a new WIP tote every 5 minutes
and 21 seconds and the cartoner consumes 1 WIP tote every 4 minutes and 30
seconds. If one WIP tote was delivered to the cartoner every six minutes, to account
for travel time, the cartoner would run at a deficit of 1050 tubes per hour, if the
system ran optimally at 80 cartons per minute.

The current average wait time

between finishing the filling process and beginning the cartoning process is 255
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minutes. If a one hour buffer of 4200 tubes was generated while the cartoner was
finishing its last hour of its four hour setup and a newly completed WIP tote was
brought every six minutes, the cartoner could run for four hours. Regardless of the
time of day, there is a 15 minute break every two to two and a half hours, and a
lunch/dinner break every four to four and a half hours. If more operators were
trained on the filling machine, they could keep the machine running during the two
15 minute breaks and 30 minute lunches to create new buffers, while the operators
on the cartoner shut down during their breaks. This coverage through breaks would
result in 1050 tubes during break periods and 2100 tubes during lunch for a steady
replenishment of the buffer stock to ensure smooth production.
6.2.4 Facilities

6.2.4.1 5s for Facility
FDA regulations require that the manufacturing areas be clean (shine) and
follow SOP's (standardize), which leads many in the pharmaceutical industry to feel
that only the remaining 3s applies. Storage areas are less strictly monitored and
XYZ Pharma is in dire need of a 5s plan for its production warehouse area.
Although the wall does contain signs to indicate where incoming and outgoing
material belongs, it is rarely followed due to the lack of free space. There are pallets
with materials that do not belong there which should be returned to long term storage
or other locations. There are no markings on the floor to alert material handlers
where materials can safely be stored without obstructing walkways.

Material

handlers waste movements when they must repeatedly move materials to access
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blocked pallets. Usually materials that are blocked tend to be left in the storage area
long after they have been used or needed, which may be considered an inappropriate
long term storage area by the FDA.
Sort:

By evaluating the contents of the current production warehouse area and

removing unnecessary materials, the flow of the product will be greatly improved.
Stabilize: Creation of designated "homes" for raw materials, finished goods, pallet

trucks, recyclables, etc. will facilitate the rapid identification of materials that are out
of place or in need of attention. Shine: All of the cardboard boxes and empty
material drums should be removed and the loading dock and production warehouse
area should be power washed. Standardize: Create standard operating procedures,
which are based on visual information, such as simple diagrams and cartoons to
indicate the proper method to store and remove material. Create a regular schedule,
every three to four days, for empty drum removal. Sustain: Create a reward system
for maintaining the area and following the standardized work. Incorporate cleaning
and organization into employee's jobs, and utilize down times to ensure the work
place is maintained.
6.2. 5 Equipment
6.2.5.1. Visual controls to decrease setup times
Incorporate visual control techniques into the equipment and manufacturing
areas. Use shadowboards for mechanics tools and for parts used in equipment setups
(tubes, valves). Some setups have over 50 individual components that are placed on
a moving cart where QC inspects them, but QC is unable to identify whether parts
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are missing or in excess. If parts are missing, the setup process is disrupted and
results in the mechanic having to track down the proper tool or part. Additionally,
manufacturers can easily assemble kettle components, such as rubber blades of the
sweep mixer incorrectly, which can have severe impact on the product. While the
manufacturers and mechanics are highly trained, these suggestions would benefit
new employees being trained and help the current staff avoid errors. These measures
would facilitate cross training of employees and give more employees a broader
system's perspective.
6.2.5.2. Autonomation
The incorporation of autonomation to a number of locations at XYZ Pharma
would result in improved product quality and fewer operators needed on machines.
Currently, the beverage industry commonly uses online sensors to monitor filling
rates and accuracy during production, thereby removing the need for end product
content uniformity testing which is currently a time consuming and labor intensive
FDA requirement (Jeffries, 2003).

The addition of online sensors to the filling

machines at XYZ Pharma would allow operators more freedom to attend to other
tasks and decrease the total number of operators required. These operators could be
reassigned to other areas or serve to cover break periods.
Specifically, the IWKA® is pre-wired but not equipped with a sensor to
monitor the loading of empty tubes. The sensor would automatically shutdown the
machine in the event of a misfeed or a tube jam. This is a common problem which
currently requires an operator to monitor tube feeding.
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The hopper is also

susceptible to bulk product overflow, where currently a mirror is the only equipment
used to monitor the fill height. Ultrasonic sensors have been employed for a number
of years by biotechnology, oil, food and other industries for processing monitoring
and control, automotive techniques and chemical analysis. (Hauptmann, 1998)
These sensors have evolved into low cost tools which could monitor hopper fill
levels, as well as monitor the bulk material viscosity and homogeneity for enhanced
online monitoring.

6.2.6 Personnel
6.2.6.1. Cross Training Personnel
The current training of operators is performed on the job. Most operators are
trained on two to three pieces of equipment and rotate when needed. While job
rotation is performed, it could be expanded. The new IWKA® filling machine is
operated by a select team of operators and is limited to one shift. By increasing the
number of operators that can run the machinery, the overall processing time could be
increased. As there is a surplus of operators, and often slow periods are used to build
boxes for later use, training could be accomplished during these points. Also, by
creating a rotating team of cross trained employees to cover break and lunch periods,
machines would remain operational and keep pace of production at a level pace. An
additional mechanic for the third shift is required to setup and maintain the filling
machinery, which they are currently in the process of training.
Additional areas for cross training could include cleaning responsibilities. To
alleviate both the mechanics and the manufacturers, operators could rotate into the
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cleaning area to sanitize equipment parts during changeovers. This would decrease
waiting times and give mechanics and manufacturers greater time to use their skills
for specialized tasks.

There are only two manufacturing specialists currently

operating 5 days a week.

Cross training other employees in basic areas of the

manufacturing specialist's responsibilities such as prep work, setup and changeover
would also give the manufacturing specialist more time.

If a manufacturing

specialist is sick, their manufacturing area is not used which results in greater
product lead times.

Training additional personnel to formulate would alleviate

problems arising from unexpected work absences, as well as increase the capacity to
produce during the weekend.
6.2.6.2. Off shift personnel
In addition to cross training employees, off shift personnel could decrease a
significant portion of non value added time that is currently experienced. A small
team of personnel could perform a number of tasks during non operational hours
(10:30pm - 5:30am) to improve flow during operational hours. Cleaning would be
the primary responsibility of the team. Areas would include cleaning formulation
kettles, parts for equipment setups, empty raw material drums and the facility itself.
Material movement would be the other focus, such as cardboard for recycling,
components for return to the production warehouse area and raw materials for
production the next day. The truck for inter building deliveries could be stored at the
production facility loading dock and loaded throughout the night in order to remove
unneeded materials.
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6.3 Development of the Future State ProModel® Simulation

Table 7. 23 Factorial Design of Three Factors Selected for Experimentation
Factors
Runs

1
2
3
4
5

6
7
8

A
0
0
0
0
1
1
1
1

B

c

0
0
1
1
0
0
1
1

0
1
0
1
0
1
0
1

Factor A is the addition of the Kalex® filling machine.

This machine is

operated by three operator teams during the first and third shift, with a total of 17
hours of available manufacturing time. This machine operates to the specifications
given in the description of the filling process of product X. If there is no cross
trained operators available, they are pulled from available Operator_ 1 or Operator_2
groups. If there is no change in the batching rules, the new machine will feed the
current IWAK_WIP_Holding area and is moved when 21 WIP Totes have been
accumulated from the two machines on the shared pallet.
Factor B is the cross training of personnel. By training operators on all of the
machinery, work assignments are made from a general pool of available operators
and can cover all the hours of operation on all machines. Additionally, material
handlers have been given the option of assisting the mechanic in the movement of
hulk drug materials and the driver to move raw ingredients and finished goods.
Mechanic_2 has been trained for the third shift, while the fust mechanic has been
moved from the second to the first shift. In the case of a cross training scenario
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without the addition of the second filling machine, the 3 dedicated operators from the
IWKA ® will be cross trained and distributed. Operator_ I and operator_2 will each
gain one operator and have 8 each; the odd operator will be removed and considered
reassigned.
Factor C changes the batching rules during production.

First, bulk drug

substance is no longer transported in one large transfer vessel. Formulated bulk is
now divided into four 55 gallon drums and transported individually to the filling
machines.

WIP totes created after filling the product into tubes are no longer

batched 20 totes to a pallet prior to transfer to the cartoner. Instead, the totes are
moved by any available operator or material handler after each tote is filled. Totes
can be moved on wheeled carts by anyone and no longer require pallets or jacks to
move them. Final QC reconciliation is no longer performed after all of the finished
goods pallets have been completed. Additionally, the finished goods pallets are
moved out of the production warehouse area after they have been reconciled and are
shipped to the customer from the warehouse building.
6.3.1 Assumptions of the Future State ProModer Simulation
1. 151

shift

(5:00am

2:00pm)

1s

comprised

of

the

mechanic,

material_handler_ 1, and operator_ I.
2. 2"d shift (7:30am- 4:00pm) is comprised of the manufacturer and driver.
3. 3rd

shift

(2:00pm

lO:OOpm)

material_handler_2 and operator_2.
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is

comprised

of

mechanic_2,

4. The "operator" group has been reassigned and operator_! and operator_2
consist of a pool of 10 operators each.
5. 2 pallets of Raw_Ingredients_Drum and 2 pallets of Raw_Boxed_Ingredients
are delivered in each arrival and are brought directly to the manufacturing
area. Excess is only stored in the formulation holding area.

Additional

arrivals are triggered when the formulation holding area is emptied by the
manufacturer as a pull system.
6. Completed formulation of bulk drug is transferred with milling to four 55
gallon drums, capable of transporting up to 225 kg each, named
Bulk_Drug_Wip_l.
7. When a Bulk_Drug_Wip_ 1 drum is filled, it is moved to the hopper by
material_handler_ 1, material_handler_2, or the mechanic.
8. The hopper location serves to split the Bulk_Drug_Wip_l into 21 parts,
which are routed to the first available Kalex_ 2 or the IWKA filling machine
by Operator_ I or Operator_2.
9. Kalex_ 2 and IWKA filling machines are operated from a pool of 10 general
operators during the first and third shifts.
10. An operator from the Kalex_2 and IWKA filling machines move WIP totes
as soon as they are filled and are not batched.
11. When the first WIP tote arrives from either filling machine, the Jones
Cartoner® setup begins.
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12. FGI_Pallets are reconciled by QC individually as they are placed into the
production warehouse area. Upon reconciliation, they are removed by the
"milk truck" to the main storage area or are shipped out to customers.
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6.4 Results of the ProModel® Simulations

Table 8 and figure 13 show the average throughput times of 999 simulation
replications for each of the eight ProModel® scenarios. Scenarios 4 and 8 show the
greatest improvement over the original current state throughput time. Scenario 8 is a
future state with all three factors changed, which is comprised of parallel machining,
cross training and changing the batch rules. Scenario 4 is the same as scenario 8,
except it does not use parallel machining methods. Scenario 5 only utilizes parallel
machining and is considerably worse than the original current state, scenario 1,
which demonstrates the importance of personnel and a support system to enhance
manufacturing.

Table 8. Rounded Average Throughput Times (Hr) of all ProModel® Scenarios
Scenario
1
Avg.
Throughput
(Hr)
371

2

3

4

189

284

105 406

89

5

6

7

8

161

290

110

Figure 14. Average Throughput Time for all ProModel® scenarios
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Table 9 compares all of the ProModel® scenarios and depicts the average
time per entry, which gives the average time spent by each component traveling
through the system for a given location in minutes. This table is helpful to evaluate
the effects of changes in scenarios on processing and holding times. It is important
to consider that when batch sizes change, there are a different number of entities in
the system and some locations are avoided all together. Therefore, this table is most
useful to compare scenarios with similar factors and graphs are used to illustrate
important differences.
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Table 9. Average Time Per Entry (Minutes) of all ProModel® Scenarios
Location Name

1

2

3

4

5

6

7

8

3082

598

2242

164

3061

629

2198

136

934
978
7098
55
354
203

1584
631
0
0
11
226

943
986
4537
97
493
132

1458
154
0
0
33
99

939
979
8912
304
1127
222

1076
119
0
33
207
235

939
980
5021
235
785
126

1140
87
0
1
171
171

1398
0
1816
0
143
27

3266
658
33
0
117
22

1411
0
1021
0
112
31

1909
147
9
0
63
25

1404
1262
46
44
172
26

1560
385
31
27
142
40

1404
734
22
32
118
41

1576
112
9
20
75
169

Inventory Transfer
and Holding_
Production
warehouse Area
Formulation
Holdin__g_ Area
Storage Vat Load
Vat Holding Area
IWKA WIP Holdin_g_
Jones WI P feed
Jones FGI

E!E!ipment
Lee Kettle
Hopper
IWKA
Kalex 2
Jones Cartoner
Pallet Wra.EE_er

Figures 15 and 16 compare the effects that changing batching rules has on
raw ingredient storage. Interestingly, time spent in the formulation holding area
which is directly adjacent to the manufacturing area is about 400 min greater on
average for the continuous processing models. This increased holding time in the
area may appear to be a negative finding for decreasing batch sizes, but in effect the
amount of time materials spend in the production warehouse area will decrease the
overall inventory and clutter. Raw materials are spending more time in the area
designated for them, instead of a general "dumping area" which occurs currently for
raw materials when the formulation holding area is full. By decreasing the amount
of materials that are delivered to meet the formulation requirements for the day, they
are decreasing the necessary time to move materials multiple times. This decreased
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material movement is particularly true when materials are blocking other items that
are needed and must be moved to access them.
The effects of changing the batching rules to a more continuous approach
additionally impact the outward flow of finished goods. The batch methods store
materials longer in order to create a batch and subsequently cause a buildup of
inventory in the production warehouse area. Figures 15 and 16 group the average
time spent per entry of raw materials and palletized finished goods together for both
the traditional batch processing scenarios and the future state batching rules. The
differences in the approaches yield considerable time savings, occupying the
production warehouse area for approximately 50% less time. This can be accounted
to the JIT QC approach, which would reconcile the finished goods as they are
completed and would be removed by one of the "milk runs" or outside shipper.
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Figure 15. Raw Ingredients Holding Time for Batch Processing
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Figure 16. For scenarios implementing more Continuous Processing
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Figures 17 and 18 describe the effects changing the batching rules on the time
WIP is held in the system. The two figures are on largely different scales, due to the
long holding times experienced in the traditional batch process. The time the bulk
drug product spends in the transfer vat holding area is extremely long. XYZ Pharma
will often wait to batch and have three formulated transfer vats of Product X, ready
for filling to avoid having to setup their filling machines multiple times. This results
in large inventories of WIP, being held for a number of days. Other areas of WIP
holding are also greatly decreased because the flow of materials has changed from
pallets to WIP totes. The filling machine must no longer create an entire pallet of
WIP totes prior to their transfer. Instead, as a tote is filled, it is transferred to the
next station by any available operator or material handler. Additionally, material
handlers are no longer necessary to move pallets of WIP totes and are free to assist
other operations.
Decreasing the amount of WIP in the system is an important goal of lean
manufacturing.
liability.

WIP crowds the plant's floor space and should be considered a

Since XYZ Pharma is a contract manufacturer they are not paid to

manufacture WIP, but are paid for their finished goods.

This lean thinking

challenges the manufacturer to decrease the lead times in order to make more money.
This methodology is in stark contrast to the traditional approach of a large WIP
inventory, which may appear to be giving the manufacturer an economy of scale.
Additional inventory in the system will hide problems such as defects, inefficiencies,
long setup times and long lead times, while incurring the costs of storage and
delayed lead times (Liker, 2004).
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Figure 17. Holding Time for WIP in the System for Batch Processing
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Figure 18. Holding Time for WIP in the System for more Continuous Processing
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8

Figure 19 compares the average time per entry (min) that a box of finished
goods inventory spends waiting after completion of operations at the Jones®
cartoner. The time spent on the pallet waiting to batch for the final finished goods
pallet is currently unavoidable.

In an ideal setting, palletizing would be an

unnecessary step and boxes would be shipped as soon as they had been completed
and reconciled.

Unfortunately, due to QC testing and customer requirements

decreasing shipments to single pallets instead of individual or groups of batches, 6
pallets each is the best approach. Scenario 4 spends approximately 50% of the time
as the current state, scenario 1, while scenario 8 only reduces the average time per
entry (min) by 15% of the current state. Additionally, scenarios 3 and 7 reduce the
average time per entry by roughly 35% each. The common factor among these four
scenarios is the cross training of employees. Since the IWKA® filling machine is
operated for two shifts in these scenarios, the probability that the Jones®cartoner will
be waiting for material is reduced and time spent waiting to accumulate enough
boxes to fill the pallets will be decreased. Cross training will result in more available
material handlers, as they are assisted by the driver and operators in other areas of
production.
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Figure 19. Finished Goods Inventory across all scenarios
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Table 10 shows the utilization(%) of locations in the model, which is useful
to identify possible new bottlenecks created in the system after changes have been
made. An increase in utilization can not automatically be described as a bottleneck.
"A bottleneck is any resource whose capacity is equal to or less than the demand
placed upon it. And a non-bottleneck is any resource whose capacity is greater than
the demand placed upon it" (Goldratt, 2004). For example, a utilization of 99% does
not constitute a bottleneck if it is able to meet demand. Fluctuations and variability
in the system must be accounted for with excess capacity to prevent the formation of
bottlenecks throughout the system. Therefore, the utilization can be used to identify
locations for further investigation.

Many manufacturers strive to reach high

utilization rates for expensive machinery and research has shown that this can result
in a large buildup of WIP in front of the machine to avoid starvation (Li, 2007). This
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buildup of WIP has negative effects on the system and can be seen from the batching
used at XYZ Pharma.
Table 10. Utilization (%) of locations
Location Name

Inventory
Transfer
Holding_

1

2

3

4

5

6

7

8

and

Production
Warehouse Area
Formulation
Holdin_g_ Area
Stor<!Q_e Vat Load
Vat Holdin_g_ Area
WIP
IWKA
Holdif!9_
Jones WI P feed
Jones FGI

0

0

0

0

0

0

0

0

13
13
32

42
67
0

17
18
26

69
30
0

12
12
36

36
16
0

16
17
29

54
17
0

1
4
14

0
0
32

1
7
13

0
1
25

3
12
14

0
5
37

4
12
12

0
7
40

19
0
25
0
16
2

86
70
74
0
26
3

25
0
18
0
17
3

91
28
36
0
25
7

18
16
25
23
18
2

52
13
45
37
37
8

25
13
19
19
18
4

74
23
26
26
31
45

Eg_up_ment
Lee Kettle
Ho_e_e_er
IWKA
Kalex 2
Jones Cartoner
Pallet Wrapper

Figures 20 and 21 give a graphical representation of the effects of changes on
the utilization of locations throughout all of the scenarios.

Figure 20 shows the

locations which are used for inventory transfer and holding.

Increasing the

utilization of holding and transfer areas is not the goal of lean manufacturing and
implies that raw materials or WIP is occupying holding areas adding to non value
added time. Therefore, utilization alone must not be misinterpreted and compared
with figures 15 through 19, the overall holding time has been decreased in scenarios
utilizing changes in batching rules. Subsequently, inventory is occupying holding
and transfer areas for a greater percentage of time, but is occupying the locations for
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shorter periods of time overall. In certain scenarios locations such as the transfer vat
holding area, the IWKA® WIP holding area, and the Jones® WIP feed area have all
been avoided or reduced to negligible utilizations.
Figure 21 describes the utilization (%) of the plant's processing equipment.
All scenarios except scenario 5, showed increased utilization of the Lee® Kettle,
regardless of the factors changed. The greatest increases in utilization of the kettle
occur when the batching rules are changed, as can be seen in scenarios 2, 4, 6 and 8.
The usage of drums to transport the materials results in down line processing
beginning sooner. Because utilization is calculated as the percent of the location
capacity occupied and little has been changed to alter the formulation procedure,
other than the arrivals of raw materials, the same amount of formulation time appears
as a greater percentage when the system throughput times are decreased.
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Figure 20. Utilization(%) of Inventory Transfers and Holding
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Figure 21. Utilization(%) Equipment
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Scenario 4 has been identified as providing the lowest throughput time (Hr)
out of the 8 tested scenarios. Following the continuous improvement philosophy, the
next phase of improvements would address the new locations which have
subsequently become bottlenecks in the system. The addition of cross training and a
change in the batching rules has shifted the bottleneck to the formulation step. The
utilization of the Lee® Kettle has increased from 19% to 91 %, which strongly
suggests further improvements to setups, cleaning and removal of other non value
added operations. If minimization of non value added time does not relieve the
formulation bottleneck, parallel machining should be investigated. The inventory
transfer and holding areas experience a large increase from the current state in
utilization of the formulation holding area from 13% to 69%. Further improvements
would consist of a more precise JIT system, which would bring the correct amount of
materials for formulation at the time the manufacturer required them.

The

improvements in scenario 4 improve upon the current system by spreading out the
arrivals of the raw materials, but inventory is still held in the formulation holding
area. If this JIT system was instated, the current formulation holding area could be
converted into a processing area, or other purposes.

6.4.1 Statistical Analysis of Results

To determine whether the three factors and their interactions are significant a
full factorial design was analyzed. The adjusted R2 value is defined as, "a statistic
that is adjusted for the 'size' of the model, that is, the number of factors"
(Montgomery, 2005a).

The adjusted R2 value is correlated with the amount of
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2

explained variability. Adjusted R was calculated to be .89, which indicates that
model is expected to explain 89% of the variability in the data. This value is given
2

in Table 11 , along with the unadjusted R , number of observations and the root mean
square error. The summary of fit and the lack of fit tests are statistical methods to
determine whether there is an unacceptably high level of variability in the system
due to factors which do not belong in the model.
Table 11. Summary of Fit
RS_g_uare
RS_ciuare A<ii_
Root Mean S_quare Error
Mean of Re~onse
Observations

0.891288
0.891207
37.63837
239.5579
7992

Table 12 shows that the calculated maximum R2 , .896, is very similar to the
summary of fit's adjusted R2 which indicates that the model does not have a lack of
fit. The calculated P value is less than .05; therefore, the hypothesis that this model
is adequate has less than a 5% chance of being rejected (NIST, 2006).
Table 12. Lack Of Fit
Source
Lack Of Fit
Pure Error
Total Error

DF
1
7984
7985

Sum of S_quares
491648
10820280
11311928

Mean Square
491648
1355
MaxRSq

F Ratio
362.7742
Prob> F
<.0001
0.8960

Table 13 is the analysis of variance (ANOVA), "tells us whether there is a
difference among means. It does not tell us which means differ" (Montgomery,
2005b). The P value is given as zero, which indicates that the difference in means is
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statistically significant.

In order to determine which factors differ and if it is

significant the effects test was performed in table 14.

Table 13. Analysis of Variance
Source
Model
Error
C. Total

Sum of Squares
92742617
11311928
104054545

DF
6
7985
7991

Mean S_quare
15457103
1416.6472

F Ratio
10911.05
Prob> F
0.0000

Table 14. Effect Tests
Source
Parallel MFG
Cross Train
Batch
MFG*Cross
Parallel
Train
Parallel MFG*Batch
Cross Train*Batch

N_Qarm
1
1
1
1

DF
1
1
1
1

Sum of Squares
40767
14217695
77386070
1147

F Ratio
28.7772
10036.16
54626.21
0.8099

Prob> F
<.0001
0.0000
0.0000
0.3682

1
1

1
1

514934
582003

363.4881
410.8311

<.0001
<.0001

The effects test in table 14 shows that all three mam factors, parallel
manufacturing, cross training personnel and a change in batching are significant.
The interaction between each of these factors is also examined by this statistical
method. The interaction between parallel manufacturing, changing batching rules,
the interaction between cross training personnel and changing the batching rules are
both significant interactions. While the interaction between parallel machining and
cross training are not a significant interaction. The non significant interaction is
most likely due to the overpowering effect of changing the batching rules. Changing
the batching rules has the strongest effect on the outcome which is demonstrated in
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the prediction profiler, figure 22 and the Pareto chart, figure 23. This dominant
factor effect results in significant interactions with the other factors.

Figure 22. Prediction Profiler of the Factors
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Figure 23. Pareto Plot of Estimates
Term

Estimate

Batch
Cross Train
Cross Train*Batch
Parallel MFG*Batch
Parallel MFG
Parallel MFG*Cross Train

-8.02691
2.25854
0.37890

'---~~~~~~~~~~~~~~~

Even though all of the factors and interactions except one, parallel
manufacturing and cross training, are statistically significant, that does not imply that
they all have the same effect on the outcome.

Figure 22 shows parallel

manufacturing having virtually no effect on the throughput time, while cross training
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and batching changes have greater impacts. Figure 23, the Pareto chart, quantifies
and ranks the effects of each of the terms and interactions.
6.5 Future State Value Stream Map

The future state value stream map was created based upon results found from
scenario 4. This scenario yields the lowest simulation throughput time which is the
primary goal for a contract manufacturer. In contract manufacturing overproduction
is not a concern because company XYZ Pharma only produces what their customers
have ordered. This scenario utilizes cross training and change in batching rules to
decrease lead times. Differences from the current state with regard to cross training
are the increase in shifts that are available for the IWKA® filling machine to operate,
due to a greater number of operators able to run the machine. The most significant
factor that was found through the statistical analysis was the batching rule changes.
These changes affect the entire process from arrivals to departures of finished goods
inventories.

Arrivals of raw ingredients are limited to quantities required for

formulation of bulk drug at that time and are stored directly outside of the
manufacturing areas. The replacement of the transfer vat with more flexible and
mobile drum has decreased waiting times during transfers and setups, subsequently
decreasing the cycle time by approximately 90 minutes. Another benefit of earlier
bulk drug substance arrivals are the completion of final adjustments to the filling
equipment sooner.

Waiting times have also been decreased because WIP is no

longer waiting to batch prior to movement. Bulk drug in drums, WIP totes and
finished goods pallets are all moved individually, and require fewer quantities to be
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moved.

The cumulative effects of these changes result in a lead time of

approximately 2130 minutes which is about a 75% reduction of time. It is important
to note that this future state finds the time to produce the frrst pallet of finished goods
inventory. The future state no longer waits to batch the finished goods prior to
shipping; therefore, this estimate is useful to determine how quickly finished goods
would be ready to begin shipping if there was flexibility with the customers to
receive goods in more frequent smaller delivery amounts.
This future state is based upon the scenario with the lowest throughput time
from the 8 scenarios tested. This throughput time can be considered a conservative
estimate. Many of the effects of the suggested improvements to areas of need could
not be readily quantified or modeled. Many of the other lean techniques discussed
earlier in the areas for improvement would further impact the lead time.

One

example is implementing quick changeovers to decrease setup and adjustment times
have been shown to decrease the necessary time by 20-40% (Centers and West,
2001 ), which could also help XYZ Pharma. While these improvements would be
qualitative, they could have both direct and indirect impacts on the total throughput
time of the system.
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Figure 24. Future State Value Stream Map based on Scenario 4
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379 Min

I

Lead Time= 2375
Min 50 Sec
(17 .5 Hr Shift)
2.26 Calender
Days

No. of Ops: 7

3 Shift

Batch Size :
8771'g

FGI
Reconcilled By
QC

Uptime: 50%

CIT : 379 Min

Reject: 0%

6;~'""

.--

(72 Ct. each)

J

Value Added =
381 Min 50 Sec
L

160 Sec

I

60 Min

I

316 Min

I

145 Min

alue Added=
16%

6.6 Chapter Review

This chapter presented the results of the current state ProModel® simulation
and the theoretical future state simulations. While all of the three factors tested were
found to be statistically significant, changing the batching rules was found to have
the greatest effect. Only one of the interactions of the factors was found to be non
significant, parallel manufacturing and cross training.

Interestingly, scenario 4,

which incorporated cross training methods and a change in the batching rules,
yielded the lowest simulated throughput time. A future state value stream map was
created to help visualize the improvements and the specific areas that had been
changed.
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Chapter 7
7.0 Conclusions

Lean manufacturing techniques should be explored in the pharmaceutical
industry to improve current systems and utilized early on in the development of new
systems. This case study represents a number of possible opportunities for specific
areas of improvement as well as suggesting an overall change in manufacturing
mindset. The pharmaceutical industry can learn a great deal from outside industries
where competitiveness is required to ensure solvency.

7.1 Linking Pharmaceutical Manufacturing to Outside Industries:

7.1.1 Approach to Manufacturing

Contract manufacturers of pharmaceuticals only make what is ordered by their
customers and use a general pull production system. Usually extra finished goods
are not manufactured or warehoused, due to the chance of expiration, loss of
contract, or removal from the market. With many of their products having only a
two to three year expiry period and products spending weeks to months traveling
through complex distribution chains, especially for larger national retailers, the
window of opportunity to sell their products is narrow. Also, preprinted tubing is
shipped by the customer to be filled with product, resulting in a finite number of
products

which

can

be

manufactured,

overproduction.
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thus

limiting

the

temptation for

While orders are made to meet customer orders, the internal flow of product
is pushed through the system. This is due to batch processing which results in
materials being pushed onto down stream machinery. This method then results in
manufacturing of as much of the order as possible in their shift, which is then
batched to move to the next process. There is a lack of production leveling which
results in uneven production of materials.
7. 1. 2 Quality

The focus on product quality is extremely high in the pharmaceutical industry
to avoid potentially fatal and costly defects. While PAT is an emerging resource,
many tools are used to ensure that the product meets the rigorous specifications
required to be safe and efficacious. The pharmaceutical industry is in the process of
moving away from end product testing and toward in process testing which has been
used for many years by other industries.
Product quality for pharmaceuticals comes at a price. The pharmaceutical
industry carries a large amount of inventory "just in case" and face problems other
manufacturing industries may not. Large quantities are held in inventory for two
reasons, 1. The average lead time for custom components is 4-6 weeks and for
materials is 1-2 weeks and a last minute increase in the order size would result in a
long lead time. Additionally, components from the customer are not purchased and
may incur the cost of holding which is then build to the customer if held for long
periods of time and 2. All batches of incoming materials and components are
quarantined and require identity conformation.
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Regardless of the size of an

incoming order, only one test is required and is regarded as more convenient by
quality control. Component manufacturers are not willing to change to a more JIT
approach and experience many similar problems due to their batch mentality.
Quarantine is not an issue for most other manufacturers and requires an additional
inventory buffer to ensure that proper quantities of raw materials are readily
available.

With only a small number of capable and reliable specialized

pharmaceutical component manufacturers, they are able to dictate long lead times
without losing business.
7.1.3 Equipment

cGMP compliance requires many elements that other industries do not face.
Validated methods for cleaning of equipment and manufacturing areas are important
to decrease the chance of unsafe levels of contamination from the environment and
personnel. The cleaning required between products is rigorous in order to decrease
the chance for cross contamination between products. This results in longer time
required for setups and changeovers. If setup times are addressed as a problem and
visual controls are instituted, any significant changes to the physical equipment may
require validation from the FDA. If the process has undergone validation, the use of
two parallel machines is acceptable, but must be evaluated carefully due to long
setup times and cleaning requirements.
7. 1.4 Facility

Some production facilities have a "Job Shop" layout, with all formulation
equipment grouped near each other and products transported in large vats for filling
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and palletized totes of WIP. A redesigned layout would place all the equipment in
proximity to each other in order of flow. During formulation, the general area is kept
clean for manufacturing and is designed for ease of cleanability.

While filling

operations, it tends to generate far more scrap materials. Due to cGMP regulations,
certain layouts may not be feasible for fear of contamination to the product. An
improvement to the flow of material within the guidance can still be investigated.
Another facility problem is the storage of components and chemicals.
Storage areas for raw material and finished goods can become cluttered due to the
quarantine process and the large quantities required for batch processing. This is in
contrast to a JIT system which would remove finished goods upon completion and
store needed components close to the manufacturing line.
7.2 Study Limitations

Every effort was made to accurately capture the current state of
manufacturing for product X. Data for the model was based on four batches with
two batches using the older filling machine and two batches using the newer filling
machine.

The future state model data was based on assumptions derived from

observations and were not data collected after implementation of the suggested
improvements.

This case study does not accurately represent the entire

pharmaceutical industry, especially some of the larger companies which have greater
financial resources to investigate lean and alternative techniques.
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7.3 Future Work
Further studies using ProModel®simulation software should be conducted to
improve the process understanding and diagnosis of problems. Future areas of study
addressing DfM, failure modes effects analysis (FMEA) and design of experiments
should be addressed.

Experimenting with continuous manufacturing equipment

during the formulation process and process development should be considered,
especially for large scale and volume products. The methods and findings from this
study could be tested to see their applicability to product dedicated equipment and
facilities.
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Appendix I: Definitions of current value stream map example (US EPA, 2006b)

err

Cycle time
ChangeoYer time

CJO

Inventory
Truck sh ipment
External sources (suppliers. customers. etc.)
Electronic information flow
Movement of production material

Supermarl<st (a controlled imientory of parts

e

ithdrawal (pull of materials, usually from a supermar~:et)

D

Production kanban (c ard or device that signals to a process
hovl' many ofwnatto produce)

.-""\]1

t

0

I

Signal kanban (shO'NS when a batch of parts is needed)

I

Ka izen starburst (identifies improvement needs
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Appendix Ill: ProModel® Simulation- Current State
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Format':.ed Listing of Hodel:
C:\Documents and Set-:ings\uri u.ri\Deskt.053\model\final curren:..HOO
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------------------------
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Cost

----------- ---------------

Marehousinq_AJ:ea

Time Series
Time Series
Ti.lte Series
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Ti:e Series
Time Series
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Time Series
Time Series
Time Ser ies
Tilte Series
Time Series
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Time Series
Tim~ Series
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Formula tion_Holding_Area
Jones_wrr_ feed
Jones_cart.oner
i'allet_Wrapper

10

Jones FGI
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100 1

-

Kalex_2
IW?IA
Kalex_1

Delivery_ Truck
Cafe table

Lee_!tattle

20

IWilA_l!IP_l!olding

100 1

12

Storaqe_Vat_ Load
Vat_.Eoldino;_A..rea

- Desk

QC

Oldest,

Oldest,
Oldast,
Oldest,
Oldest,
Olde.st,
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Oldest,
Oldest.,
Oldest,
Oldes:.,
Oldest,
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Oldest,
Oldest.,

.
.
.,
.,
..

------------

Fir st

,

Oldest ,

...........................................................................................
Entities

Nama

Speed (fpm)

S-:at..1

Aa;v_InqriS1dients_Drum

lSO
lSO

Time Series

Ccst

-- -- --- ----- --- -- --- -- -- ------------ ----------- ------------

WIF_Totes

Time Series

Finished_Goods _ rr.v-ento r y lSO
Transfer_Vessel
lSO
Raw_Boxed_Ingredients
150

-FGI

Time Series
Time Series
Time Series
Time Series

150

PALLET

..................................................................................
................... ........................ ......................... ............. .............. ..
Path Net-.,,od:s

,

'
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T/S
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--- -- ------ -- --- - --- -------- - -------- --- ---Oriver_path
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path_ manufacturer Passin9

overvie·..-

Passing

Speed
Speed

S~eed

To

BI

Dist/Tiin9

'

Digcance Nl

N2

Bi

N2

N3

Bi

S6.1E
S7. 15

'

oiscance Nl
Nl

N2

Bi
Bi

215.85

'

Speed Fa ctor

---------- ------------

NS

35.66

Nl
NE

Bi
Bi

E. SS

~3

Cistance Nl

N2

Bi

71.9€

N4

NS

Bi

31. EO

!11
NS

NS

Bi

4. 95

!19

Bi

37 .23

NE

11 7

41.€0

N9

N!O

NlO

Nll

Nll

Nl2

NS

Nl 7

NS

N3

N2

Bi
Bi
Bi
Bi

10.U

Nl2

Bi
Bi

213.3S
24. 70

13. S4

18.H
4.42

NZ

N4

Bi

107 .ZJ

Nl1

N7

Bi

22B.6S

Nl7

Nl~

Nl4

N7

Bi
Bi

1Bo. l6

NlS

N3

Bi

S2 .39

41.3~

......... , ................. '+' ......................... ' ................... +• .... +• '+ .............................. .-..
Interfaces

................................................................................................................. .,............ .
Net
Driver~e-ath

Node

Location

Nl

Delivery_Trude
Warehousing_Area

N2
N3

path_ma.nufacturer Nl

overview

2ormulation_Holding_Area

Lee_Kettle

N2

Farmulation _F.oldir.g_ Area

NS

Cafe_table

N6

Storage_Vat_Load

N3

Vat_Holding_Area

Nl

Delivery_Truck

N2
N4

Warehousir.g_Area
Cormu lat ion_Hold.inq_At:ea

NS

Lee_l\ettle

N7

IWllA

N8

IWF.A_WIP_Holding

N9

Jones_ffIP_feed

Nl O

Jones_Cart.oner

Nll

Jcnes_FGI

N12

Pallet_Wrapper

N3

Cafe_table

Nl7

Storage_Vat_Load

N14

Va"_Holding_Area

N1S

cc_nesk

.................................................................. ,.. ........ *"'' ......................... .
Mapping

............. ' ....................... '+ .......... ' ..... + ..... +·•. +' ..... + ....... + •• +
Net

From

To

path_manufacturer Nl

N2

Nl

NS

Nl

N6

overview

N2

Nl

N4

N2

NS

N4

N7

NE

N8

N9

N9

Nl O

NlO

Nll

Nll

Nl2

Nl2

N2

Nl7

NS

NH

N11

N2

N4

N4

NS

t .....

+ ......... ' ...... + ... ..

Des~
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N7

NH

NS

N7

Ni
NS

Nl2
Nl7

S9

NS

SlO

NS

NU

Nl:

Sl2

Nll

Nll

NH

NH

N1

NS

li3

,, ••• ' ···-·· ....... ' '*''. ' ............. ' ' ..... ' ........ •·••• .................................. .
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Name
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Manufact~rer
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Search

tnt
Search Path

Closest Oldest path_ri:anufacturer Er!;>ty: 150 fpm
Eoite: Nl

Haterial_Sandler_ l

By Oni t

Ml: 150 fpm

Clcsest Oldest cverview
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Clcses: Oldest overview
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By Unit

iSO :pm
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Material_ha.ndler _2

(;ost

Motion

Clcsss:. Oldest Driver _path

Empty:

:pm

1s:.

!'pm

:Ull: 150 fpm

Re-me: Nl

(Return)
Mechanic

By ~nit

Closest Oldest c-:.•erview

!!l!pty: 150 fp!!
:Ull: 150 fpm

He.rte: N1

Operator_l

By Onit

;)npty: 150 fpm

Cl osest Oldest ov&rvie•.i

Full: 150 fpm

Ecime: N1

Cperator_2

By Onit

Elt;>ty: 150

Clcssst Oldest cvervis"A

operator

By Unit

Empty: !SO !pm

Clcses: Cl des: cverview

:Ull: !50 fpm

Some: N7

OC: _Inspector

By Unit

Clcsast Cldes: overview
RC<~e:

:pm

Ml: 150 fpm

Eou:.e: N10

Er,pty: 150 !pz
;'Jll: !S;J fp:n

Nl5

.................................................... , ..................................... 't.
Processinq
. . . . . . . . . . . . . . . . . . . . . t ..... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

~- rocess

Entity

L<:caticn

Ra'.i_lnqredien·t s _ Drwa.

Celivery_TI UCk

Operation

Blk

Rule

0-otput

Destination

R~• _ lnqredients _Orum

Ware!:.ous inq_Area

FIRST

Rur_Boxed_ lngredients

Marehousing_krea

FIRST

llAIT N(. 2, . 3)

VIEW "loading dock"
Raw_Boxed_Ir.qredients

Delivery_ Truck

iiAlT N(.2, .3)

Raw_ Inqrt1:dients_Drum

Warehousinq_Aiea

li<UT N(.5, .2)

VIEW "warehouse"

Raw_Bcxed_Inqtedients

Warehousinq_AI:ea

li<UT N(.S, .2)
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Ra<irr_Ingredients_ trum

Formulation_Hclding_kraa ?IRST

Raw_Bcxed_ Inqredients

E'onr:ulatitr:._Holding_:..rea FIRST

ALL

Formulation_Holdinq_Area Accum 4:
VIEW "manufacr.urinq pro::ess•

l-ee_Ke'ttle

Ra'.(_ Ingredients_Drum

tee_K~ttle

FIRST

Raa_~xed_Inqredients

Lae_Kettle

FIRST

s:orage_'lat_~ ad

P!RST

Transfer_Vessel

Vat _Holding_Area

FIRST

Transfer_Vessel

IW!'.A

Combine 4
IP S0?2=0
!KEN

Use Manufact urer for N(e:,1 0) Wait . l

S0?2=1

Ost

Manu~act u rer

to-R

N ( ~ SC ,

30}

Transfa r_Vessel
Transfer_Vessel

Storaqe_Vat_Load

OSE Manufacturer FOR N {1 20, 30)

Transfer_Vessel

Vat_F.oldinq_~.rea

liAIT

Transfer_Vessel

lil!V.

IF SO!=J

1
~(3340,

199i)

TREN

IJse

H~chanic

for N(300,SCt) Wait .1

SUT=l

Use Operatcr : cir N(495 , 42)

"IP_Totes

Ilr!V'._WIP _Holding

tIRST

WIP_Totes

IW~A_ WIP_F.oldir.g

il.CC\!ln

21

WIP_Totes

Jones_tilC:_feed

FIRST

WIP_'l'otes

Jcnes_ WIP _feed

ac::um -84

KIP_Tot.es

Jone s_car:or.e r

E'IRST

WIP_rotos

Jones_Cartaner
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OSE

~.echa.,ic
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SUTl=l
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Finis!'ted_Goods_I n~ ent o r y Jones_ FGI

Finished_G<xtds_Inventor y Jones_rGI

120

r!RST

Co=.bine 70

PAI.LZT_PGI

Palle:._Wrapper

WAlT

~(14,

Wa rehou9in9_.:...rea

PA!.LET_E'GI

Delivezy_Tn:ck

Warehcusinq_J..rea

FIRST

PAf.LET_!'GI

Oeli very _'?ruck

FIRST

?All.E1'_:-Gl

£XU
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Accum 6
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Entity
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Qty Each

Fir5t Time C<:currences Frequency
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Pallet_Wrapper
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............................................................................................ ,
IO

Type

SOT
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SOTl
SOT2

'larl
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c

Time Seriss
Time Seriss
Time Series

0

..................................................... ,.,................................................................... .

.................................................................... ...............................
Arrays

IO
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Import. File £xport File Disable

Int.eqer

Arrl

None

Persist
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Macros
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ID
Macl

subrout.ines

IO

Type
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None

Parameter
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Log ic

External Fi las

(null)
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Prompt
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IO

Sh ift
Sh ift
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Appendix IV: Pro Model®Simulation- Future State
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Storaqe_Vat_Load
Kalex_Wip_Pallet

20

OC_Desk

Hopper

21

Rules

Cost

..

Firs:.

Series Oldest. ,

Series
Series
Series
Series
Series
Series
Series
Series
Series
S6ries
Series
S&ri&s
Series
Series

Oldest,
Oldest,
Oldest,
Oldast,
Oldest,
Oldest,
Oldest,
Oldest,
Oldest,
Oldes:.,
Oldest,
Oldest,
Oldest ,
Oldest,

..
..
.
.

....................................................................................................

........................................................................................
Entities

Speed (fpm)

Name

Stats

Cost.

------------------------ ------------ ----------Raw_ Ingradisnts _ Dru:m

150

Time Series

WIP_Totes
Finished_Goads_Inventory
Transfer _Vessel
Ra·..,_BC'xed_ Inqredients
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e1 .1s

21s. es
t. 68
71. 56
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5.53

NS

NS

Bi
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NS

Nl O

Bi
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